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ABSTRACT
U.V./Visible spectral changes accompanying the inter­
actions of some organic acids with human serum albumin 
have been studied in detail.
The spectra have been analysed by means of matrix 
rank analysis to estimate the number of spectrophoto- 
metrically distinguishable species in solution. This may 
be used to estimate the number of distinct classes of 
binding sites on the albumin molecule.
A new method has been developed to obtain equilibrium 
constants and numbers of binding sites per albumin mole­
cule from spectrophotometric data.
The method involved the titration of a constant 
concentration dye solution with human serum albumin. The 
series of spectra thus obtained were analysed by means of 
a computer assisted data fitting routine. The routine was 
based on a model for the system, using two independent 
classes of binding sites on the albumin molecule. A series 
of derivatives of azobenzene were studied by the method in 
order to correlate structural features of the molecules 
with the extent to which they bound to human serum albumin.
The interactions of the azobenzene derivative series, 
with human serum albumin, were studied by an ultrafiltra­
tion technique. Projected ultrafiltration binding curves 
from the U.V/visible spectrophotometric experiments were 
found to be in agreement with those measured experimentally
Spectral changes accompanying the competitive inter­
actions between Bromophenol Blue, and the azobenzene
10
derivatives, with human serum albumin, have also been 
studied. An attempt has been made to correlate these 
results with the foregoing binding experiments.
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CHAPTER 1
INTRODUCTION
14
1.1. General aspects of drug-albumin interactions
The interactions between drugs (pharmacologically
active molecules) and blood proteins have been extensively 
studied in recent years. Binding of drug molecules to 
plasma proteins is important because drugs will not normally 
be biologically active when bound to a plasma protein 
unless they displace pharmacologically active substances 
from their binding sites.
Drugs, other xenobiotics, and endogenous compounds may 
be transported in the blood stream in simple solution as a 
suspension or bound to plasma proteins or blood cells. If 
a drug is bound in this way to one of the blood constituents 
its potential for interaction with receptor sites may be 
limited. Similarly its availability to the drug metabolism 
and excretory systems may be reduced. If these binding 
processes are weak and reversible it is likely that they 
are of little therapeutic significance. However, for 
strongly bound drugs, plasma binding may strongly influence 
a drug's potential bioavailability.
Plasma binding may also be of importance in the case of 
the displacement of a drug by a more strongly bound compe­
titor. Thus a strongly plasma bound compound, such as 
'Warfarin', can be displaced by the administration of other 
plasma bound drugs such as acetyl salicylic acid (Aspirin). 
Such effects will seriously increase the levels of free drug 
biologically available.
1.2. Human serum albumin -
1.2.1. Structure and function
1
The principal components of human blood are as follows:
Component Concentrât
Albumin 40
ot-Globulin 3.1
o^-Globulin 4.8
B-Globulin 8 . 1
Fibrinogen 3.4
T-Globulin 7.4
Erythocytes 150
15
-3
As can be seen, albumin is the principal plasma protein 
and it makes the largest contribution towards the plasma 
protein binding of most drugs, as well as interacting with 
other endogenous materials such as fatty acids and bili­
rubin. The unique binding capacity of albumin is thought 
to be necessary for the transport of endogenous materials 
in the blood, and possibly across cell membranes.
Although it is generally accepted that for a healthy 
human adult the plasma concentration is between 35 and 
45 g dm”  ^ this may alter by 10-20% with posture or during 
exercise. Many diseases also lower the serum albumin levels 
such as nephrosis, hepatitis, cirrhosis, cancers, gastro­
intestinal diseases, hypergammaglobulinaemia, malnutri­
tion, heart disease and hypothyroidism. Levels will also 
be lower during infancy, pregnancy, senility and in indi­
viduals suffering from the effects of stress, injury, 
alcohol, and acclimatisation to heat.
Higher levels of endogenous substances which compe­
titively bind with albumin such as fatty acids or bilirubin 
will also decrease the level of albumin drug binding.
The albumin molecule consists of a single polypeptide 
chain with an isoelectric point at pH 5.0. At pH 7.4
16
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Fig. 1.1. Amino acid sequence of human serum albumin.
Residues assigned by analogy with bovine 
serum albumin are shown in lower case 
letters.
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(physiological pH) it, therefore, carries a net negative
charge (arising from C terminal, aspartic, glutamic and
tyrosine residues). It also carries a smaller number of
positive charges (arising from histidine, N-terminal, Lysine
2
and arginine residues).
The albumin molecule appears to exist partly as an 
a-helix and partly as a random coil. At pH 4.0 albumin 
undergoes a conformational transition which results in an 
increased viscosity and greater electrophoretic mobility.
Further conformational changes occur at lower pH 
values. Thus it is important that drug binding studies 
should be performed at known, buffered, pH.
The amino-acid residue sequence of human serum 
albumin proposed by Brown^ is shown in Fig.1.1. Further 
information is continued in Table 1.1. The structure is 
based on tryptic and chymotryptlc peptides. The disulphide 
bridges are based on analogy with bovine serum albumin^.
The structure is in agreement with those obtained by other 
laboratories^”^^ for various fragments of the molecule. 
Geisow^^ has described this structure as consisting of 
six a-helices (three double loops) which form a roughly 
cylindrical domain, the total molecule being made up of 
an association of three such domains (Fig.1.2).
S -S - t - î ,
r \
s-s 4-5 -I— co^ H
Fig.1.2. The double loop structure of serum albumin.
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1.2.2. Human serum albumin - preparation and purification
Commercially human serum albumin is still prepared by 
the method of Cohn^^ and his associates, this is usually 
obtainable as 'Cohn Fraction V'. Since the purity of 
Fraction V is only about 96%, re-crystallised, globulin 
free albumins are also commercially available, their pre­
paration being generally based on the method described by
18Cohn, Hughes and Weare.
Cohn Fraction V .^^
Human blood plasma is cooled quickly to 0°C without 
allowing ice formation. The pH of the solution is adjusted 
to 7.2 with an acetate buffer in an ethanol-water system 
so that the final ethanol concentration of the system is 
8% by volume. The solution is cooled to between -2°C and 
-3°C, a fraction ('Fraction I') precipitates out, consist­
ing mainly of fibrinogen. The precipitate is removed by 
centrifugation. Adjustment of the solution to 25% ethanol 
at pH 6.9 and -5°C gives rise to a second precipitate con­
sisting principally of B and 7 -globulins ('Fraction II + 
III). The fraction contains nearly all of the immune 
globulins and the isoagglutinins. Nearly all the prothrom­
bin is precipitated in this fraction. It also contains 
large amounts of cholesterol and other lipid substances.
After removal of this fraction the supernatant is 
adjusted to pH 5.2 and 18% ethanol at -5^C. A fraction 
consisting mainly of a-globulin and lipids separates out 
(Fraction IV-1). The supernatant is next brought to a 
pH of 5.80 - .05 and an ethanol concentration of 40%, the
20
ionic strength of the solution being 0.09 mol dm”^. By 
centrifuging at -5°c a fraction (Fraction IV-4) is ob­
tained consisting mainly of a-and B-globulins and some 
albumin.
At a pH of 4.8 and an ethanol concentration of 40% 
Fraction V is obtained. This fraction contains the bulk 
of the albumin present in human plasma.
Re-crystallisation
Human serum albumin may be re-crystallised from 
ethanol-water mixtures usually with the aid of some other
organic reagent such as decanol, chloroform, or benzene.
18The most successful method used by Cohn et al was by 
re-crystallising Fraction V at -5°C from a solution con­
sisting of 25% ethanol, 0.2% decanol at a pH of 5.4, and 
an ionic strength of 0.15 mol dm”^, attained by the addi­
tion of sodium acetate solution.
Laminar crystals are obtained in 90% yield after 
standing for several days.
Removal of fatty acids
Re-crystallised human serum albumin may still contain 
fatty acids bound to the protein. Chen^^'^^ has described 
a method for their removal. To a 10% w/w solution of 
albumin in water is added charcoal (5% w/w) and the pH 
of the solution lowered to 3.0 by the addition of hydro­
chloric acid (0.2 mol dm”^). The charcoal is removed by 
centrifugation, and the solution then brought to pH 7.0 
by the addition of 0.2 mol dm”  ^sodium hydroxide. The 
protein in this solution may be used directly, or re­
precipitated at pH 4.8 as described previously.
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1.3 Methods of studying protein-drug interactions
Many methods have been explored in the determination 
of albumin binding of small ions and molecules. The most 
important of these are outlined below. In this instance 
all species bound to the protein molecule will be referred 
to as 'ligands', even in the case of metals. This is a 
reversal of the usual convention in which the protein would 
be described as the ligand binding to the metal.
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1.3.1. Dialysis^^'^^"
This is by far the most widely used technique, and 
the major part of the data found in the literature concern­
ing quantitative aspects of albumin-small molecule inter­
actions has been determined by this means. At its simplest 
the technique takes the form of fig. 1.3.
Semi permeable membrane 
Ligand + protein solution 
Ligand solution
Stirrers
Fig.1.3. Schematic representation of a dialysis 
experiment.
The protein component is confined within a semi- 
permeable membrane through which unbound ligand molecules 
can freely diffuse. At equilibrium the unbound ligand 
activities on both sides of the membrane must be equal, and 
any increment in the protein compartment is presumed to 
represent bound ligand.
Being the most widely used technique for measurements 
of this kind comparison with other workers is easy.
22
However, the technique suffers from several drawbacks.
Both protein and ligand may bind to the dialysis membrane. 
The Donnan effect must also be considered and appropriate 
corrections made in the case of ionic ligands, especially 
where the total ionic strength is low. Non-physiological 
conditions and prolonged equilibration times may cause 
bacterial contamination and protein dénaturation.
1.3.2. Gel Filtration23-25.
The method has certain similarities with equilibrium 
dialysis. Generally a sephadex column is equilibrated 
with a solution of ligand.
A small volume (relative to the total volume of the 
column) of protein, dissolved in the equilibrating solution 
is applied to the top of the column. The column is eluted 
with the ligand solution.
After passing through the column the solution in 
the vicinity of the protein will have essentially returned 
to the equilibrium concentration, having removed ligand 
from the gel. Consequently the solution eluted imme­
diately behind the protein band shows a marked reduction 
in ligand concentration. The ligand concentration is 
usually followed by U.V/Visible spectrophotometry.
2 2 7
1.3.3. Ultracentrifugation '
If a solution containing protein and a small molecule 
is subjected to the influence of a centrifugal field there 
will be a redistribution of the molecules in accordance 
with the thermodynamic equations for sedimentation equi­
librium. At relatively low centrifugal fields (about 10^
X gravity) the redistribution of molecular mass about 10^
23
is such that the concentration in the ultracentrifuge 
cell with a ligand column height of 3 mm varies about
30 fold when sedimentation equilibrium is achieved.
2
Small molecules with molecular masses of about 10 under 
such field would be virtually uniformly distributed 
throughout the cell. At the same time the chemical 
equilibrium must be maintained at each level in the 
ultracentrifuge cell and, therefore, the total concen­
tration of drug must vary with the concentration of 
albumin. Observation of the variation of protein con­
centration (e.g. by interferometry) and ligand concen­
tration (e.g. by absorption spectrophotometry) can 
yield the information required to give dissociation 
constants and the number of binding sites per molecule 
in the system. The theory for the sedimentation 
equilibrium technique is rigorous and its application 
straightforward. Assumptions and approximations which 
must be made are minimal and subject to experimental 
test.
Sedimentation velocity methods have also been 
investigated, although they are theoretically not so 
satisfactory. Experimentally, however, they are more 
rapid, and often simpler to apply.
1.3.4. Electrophoresis^^~^^
Small molecules (especially ionic compounds) when 
bound to the albumin molecule should change the electro­
phoretic mobility of the molecule. However, since an
H.S.A. molecule at pH 7.4 has about 100 positive charges 
the binding of two molecules, even if totally by an 
electrostatic interaction will only decrease this charge
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by about 2%,
The method can be useful for obtaining qualitative 
information, and has the advantage that multiprotein 
mixtures can be used if necessary. It is usual for a 
Tiselius type apparatus to be used, whilst boundaries are 
observed by means of a Schlieren technique.
The success of the method depends on two character­
istics of electrophoresis.
a) The velocity of an ion in a given potential gradient 
depends on its charge and, therefore, in part, on the 
number of small ions with which it is combined.
b) Although as the boundary moves the more highly charged 
ions move faster, there is a continuously instantaneously 
re-established equilibrium so that the boundary moves with
a constant average velocity Op, which is related in a linear 
fashion to the averagemolal ratio in the protein complex.
The velocity is, of course, affected by the entire environ­
ment, (other electrolytes present, counterions etc.) so 
that the relation of Op, and the extent of complex forma­
tion applies strictly only to conditions in which the 
environment undergoes no change other than small increments 
in ligand concentration. Even when this restriction is 
satisfied, it is necessary to make the assumption (which is 
known to be invalid for a number of linear polyelectrolytes) 
that .the potential increment due to each anion bound is 
not altered as charges accumulate. i.e. the ratio of 
counterions accompanying the ion, to ions bound, does not 
depend on total or net charge. It is also necessary to 
assume that the frictional coefficient which depends on 
conformation does not depend on the extent of complex formation
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31— 3 51.3.5. Nuclear Magnetic resonance.
When a ligand is bound to a protein the relaxation 
characteristics of one or more of the protons of the ligand, 
or one or more of the protons of the protein may be altered.
This alteration may show up as a 'chemical shift', 
frequency change, or as the broadening of a line in the 
proton magnetic resonance spectrum.
Selective broadening of some of the protons resonances 
of the small molecule is always observed when it is bound 
to a protein, and has been interpreted as a sign of inti­
mate contact between such protons, or the groups to which 
they belong, and the macromolecule. The chemical shifts 
are small and difficult to measure, they arise from rapid 
reversible changes of the state of the ligand from bound 
to unbound, and reflect not only the shifts in the nuclei 
which are caused by binding, but also the time average of 
the fraction of ligand bound.
1.3.6. Fluorescence Spectrophotometry^
Fluorescent molecules, when combining with protein, 
frequently show a change in the intensity or polarisation 
of the radiation emitted.
Daniel and Weber^^ for example, studied the inter­
action of l-anilino-8 -naphthalene sulphonate (A.N.S.) at 
various extents of combination with bovine serum albumin.
The fluorescence spectra of the A.N.S.-B-S.A. complexes 
(fig.1.4) show that as the average number of molecules of 
ligand per molecule of protein (n) increases, the A.N.S. 
fluorescence (xmax 469nm) increases, concurrently the 
protein fluorescence(Xmax 343 nm) decreases.
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Fig.1.4. Fluorescence spectra of ANS-BSA at
various values of n. B-S.A. concentra­
tion lOg dm” in 0.1 mol dm” buffer pHT.O. 
Bandwidths of excitation and emission 3nm.
An isoemissive point is observed at 416 nm.
They attributed this protein fluorescence to tyrosine 
and tryptophan residues. Inspection of the spectra indi­
cated that the fluorescence of tyrosine was relatively 
less quenched than that of tryptophan.
They were able to treat the spectra mathematically, 
and to obtain values for the average number of ligand 
molecules bound to each albumin molecule under various 
conditions by making the following assumptions :-
(i) The quantum yield of free A.N.S. was negligably 
small compared with bound A.N.S.
(ii) The quantum yield of bound A.N.S. is at least to a 
good approximation independent of n, or is a very slowly 
varying function of n.
In the case of non-fluorescent molecules, fluorescent 
quenching of the tryptophan and tyrosine residues may be 
used for determining interactions between proteins and
27
3 7small molecules . Although it must be realised that 
such studies implicitly assume that binding occurs only 
at or very near to, the albumin tryptophan or tyrosine 
residues.
1.3.7. Ultra violet/visible spectrophotometry
The U.V/visible spectra of many compounds undergo 
changes in the presence of serum albumin. These are 
marked by a shift in the position of maximum absorbance, 
and a change in the overall shape of the absorption bands.
41Klotz , appears to have been the first to investi­
gate spectrophotometrically, interactions between organic 
anions and negatively charged proteins.
He chose for the organic anions three closely related 
compounds, Azosulphathiazole (fig.1.5), Orange I (fig.1.6), 
and Orange II (fig.1.7) using bovine serum albumin as 
the protein at pH 6.9
N = N--^r>SO^NHR R = thiazole
NaO^S
Fig.1.5 Azosulphathiazole
O^S N OH
Fig.1.6 Orange I
Na 0_S N =N
Fig.1.7 Orange II
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Azosulphathiazole was shown by Klotz to obey Beer's
— 3 — 3law up to a concentration of approximately 1 0  mol dm 
From this he concluded that the dye existed in the mono­
meric state in aqueous solution at concentrations below 
— 3 — 310 mol dm . He also observed that the spectrum of 
the dye was independent of pH over the range 2 to 9.
On addition of a few hundredths of a per cent of 
bovine serum albumin the spectrum of Azosulphathiazole 
was significantly altered (fig.1 .8 ).
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Absorption specta of Azosulphathiazole
A in buffer at pH 6.92
B in buffer containing B.S.A. (0.2%) at 
pH 6.90.
The alteration could not be attributed to the formation of 
dimers or polymers, as the dye had been firmly estabished 
as monomeric in this concentration range, nor were they 
attributable to a pH change. They must, therefore, have 
been due to combination of the protein with the dye anion 
to form an intermolecular complex.
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Once an albumin concentration of 0.2% had been 
exceeded (for a dye concentration of approximately 
1 X 10  ^ mol dm^) no further spectral change was observed, 
which Klotz concluded to be consistent with total binding 
of the dye by the protein.
Knowing, therefore, the spectral shapes for both free 
and bound dye it was possible to deduce, for any B.S.A.-dye 
solution, the concentration of bound drug from the equation,
A = (eg C f + C b  C^)!
where A = the absorbance of the sample at a wavelengthX
1 = the path length
= the extinction coefficient of the free 
ligand at the wavelength X 
C- = the concentration of free ligand
e, = the extinction coefficient of the bound
b
ligand at the wavelength X 
= the concentration of bound ligand.
Similar changes were observed in the spectra of 
Orange I and Orange II, in the visible region, when these 
dyes interacted with bovine serum albumin, the extinction 
coefficients at the maxima being reduced, although no 
significant shift of the spectrum towards the red was 
observed. Methyl Orange also behaved similarly, but a 
shift in the spectrum towards the blue was observed on 
binding.
From these studies it seemed most likely that the 
sulphonate group common to all these substances was 
primarily responsible for the binding to the protein as 
in the case of albumin with detergents.
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However, it appeared that the relative effect of the 
protein on the energies of the ground and excited 
states of the dyes was dependent on the nature of the 
entire molecule and not only the character of the bind­
ing sulphonate group.
Klotz also conducted some semi-quantitative compe­
titive experiments with various simple organic acids con­
taining one, or no aromatic ring.
On addition of the acid to a standard solution of 
Methyl Orange, or Azosulphathiazole, the dye was partially 
displaced from the protein, and thus the spectrum moved 
towards that of the free dye spectrum. Measurement of 
the extinction coefficient at the maxima allowed a com­
parison of the displacing ability of the acids.
' A.')
Freedman and Johnson used the spectrophotometric 
method of Klotz to determine binding constants for the 
dye Evans Blue, (p 12)with human, bovine, canine and rabbit 
serum albumins. They showed that for canine and bovine 
serum albumin the binding data fitted better to a two 
binding site model than to a single binding site model.
In the case of humàn and rabbit serum albumin they obtained 
better values for a single site model. They also showed 
that for bovine serum albumin the binding data is depen­
dent on the ionic strength of the buffer solution contain­
ing the dye-albumin system.
Glazer^^ extended the basic methods of Klotz in an 
investigation of the binding of Biebrich Scarlet (fig.1.9) 
to the enzyme a-chymotrypsin.
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The visible spectrum of Biebrich Scarlet shows a red 
shift, and a decrease in the maximum extinction coeffi­
cient value in the presence of a-chymotrypsin (fig.1 .1 0 ). 
Glazer ascribed this to protein binding of the dye.
From the difference spectra produced as a result of the 
titration of Biebrich Scarlet with the enzyme, Glazer 
calculated a dissociation constant (without comment on
the mathematical procedures involved) of 8 . 8 x 1 0 ”^
— 1 3mol” dm , assuming a 1:1 complex. Using a gel filtra­
tion technique and a standard Langmuir isotherm treatment 
of the results he obtained a value for the dissociation 
constant of the complex as 8.9 x 10”^ mol”^ dm^ •
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fig. 1.10 Effect of a-Chymotrypsin. on the visible
spectrum of Biebrich Scarlet^ All spectra 
were obtained in 0 . 1  mol dm” phosphate 
buffer at 22^Cat a Biebrich Scarlet con­
centration of 2.88 X 10”'mol dm”  ^. A 1 cm 
light path was used in all cases.
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Curve (a) 
Curve (b)
Curve (c)
Biebrich Scarlet 
Biebrich Scarlet in presence .of 
ot Chymotrypsin (1.8 x lo”* 
mol dm” )
Difference spectrum of Biebrich 
Scarlet and a-Chymotrypsin 
(1 . 8 X 1 0   ^ mol dm”^ ) vs 
Biebrich Scarlet.
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44Lang and Lasser attempted a similar spectrophoto­
metric study of the binding of Trypan Blue, fig.1.11, to 
bovine serum albumin.
Œ
OH NH
Fig.1.11 Trypan Blue
In this instance the shape of the difference spectrum 
was not independent of albumin concentration (see fig.1 .1 2 ) 
This effect was explained as being due to a number of sets 
of sites on the albumin molecule giving rise to a number 
of complexes with differing molar extinction coefficients 
at any particular wavelength.
0.1
- 0.1<
<
- 0.2
-0.3
480 600 660540
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Fig.1.12. Difference spectra at pH 7.4 for the
Trypan Blue to B.S.A. ratios indicated. 
Trypan Blue concentration =
2.56 X 10“  ^ mol dm-3.
45Shams-Eldeen, et al used difference spectrophoto­
metry to study the interaction of Sulindac with human 
serum albumin. They published a set of difference spectra 
without any indication of the absortion spectrum of
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Sulindac either in the absence, or the presence of,
H.S.A. They did not attempt to interpret the difference
spectra quantitatively. They did, however, publish some
fluorescence quenching data which suggested that Sulindac
5 —1 3had an association constant of about 1 x 1 0  mol dm , 
although this disagreed with dialysis data from the same 
series of experiments which gave a value of 6 x 1 0  ^
mol”  ^dm^.
1.3.8. Ultrafiltration
Ultrafiltration is basically an extension of the 
dialysis technique which goes some way towards rectifying 
the problems encountered as a result of the long time 
scale required for dialysis.
Retaining
clip
Safety valve
Compressed Nitrogen
Inlet port
Rubber 
'O' RingsStirrer
Magnetic stirrer 
table
Ultrafilter membraneOutflow
pipe Porous
membrane
support
Fig.1.13 Diagramatic representation of the 'Amicon' 
ultrafiltration apparatus (Model 12)
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A representation of a commercially available ultra­
filtration apparatus is shown in fig.1.13.
A solution containing the protein and ligand to be 
observed is passed, under pressure, through an ultrafiltra­
tion membrane. This membrane will not allow macromole­
cules to pass whilst allowing small ligands to pass 
freely. The two major problems associated with the 
technique are those gf binding to the filter and rejection 
by the filter membrane. Binding of both protein and ligand 
to membrane may occur, this is usually countered by equi­
librating the membrane with the solution to be studied 
before filtration.
In many cases the ligand may not diffuse entirely 
freely across the ultrafiltration membrane, making the 
mathematical interpretation of data difficult.
The concentration of diffused ligand obtained at the 
outflow may be measured by any quantitative technique, 
although spectrophotometric measurement seems to be the 
most widely used.
46Some workers have modified the apparatus slightly 
to ensure that the protein concentration in the cell 
remains constant throughout the course of the experiment, 
in this instance the technique is known as 'diafiltration'.
These techniques have not been as widely used as 
dialysis.
4 7Farese, Mager, and Blatt , have used ultrafiltra­
tion to determine diffusible calcium in serum. Blatt, 
Robinson and Bixler^^^ made a limited study on the binding
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of Methyl Orange to human serum albumin. They obtained
binding data for the system although they gave no values
for equilibrium constants. Their data was not in close
49agreement with the data of Klotz et al. , obtained by 
dialysis.
Crawford et al.^^ have studied the interaction of 
human serum albumin with Bromosulphthalein. Again they 
produced binding data but not binding constants or site 
numbers.
1.4. Interactions between albumin and small ligands
1.4.1. Cations
Albumin shows a much smaller capacity for binding
cations than it does for anions. A number of interactions
have been studied between metal ions and bovine serum 
albumin.
Hg^ **" binds covalently at the sulphydryl group^^'^^ 
whilst Cu^ "** and Ni^ '*’ bind at the square planar chelate 
ring formed by the a-amino nitrogen, the first two peptide 
nitrogens and the primary nitrogen of the imidazole ring 
of the third his^ dine residue^^”^^. Albumins such as 
canine or porcine albumin lacking the histidine residue 
in position 3 do not bind copper or nickel as tightly.
Mn^"^ is thought to bind at the site formed between
59the a-NHg group and the imidazole group , with K =
2.8 X 10^ mol”^ dm^. Other metal cations appear to be 
less specific in their binding site and are bound less 
strongly, e.g. Co^^ (K = 6.5 x 10^ mol’L dm^),^^
Zn^+ (K = 3 X  10^ mol“^ dm^) and Cd^+ (K = 1.7 x
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10^ mol  ^ . The binding of calcium ion by serum
albumin is important physiologically, but also shows only 
a weak affiliation with K = 1 x 10^ mol”  ^ dm^ 6 6 - 6 8 ^
1.4.2. Long chain anions
Anionic detergents are well known to bind strongly 
to human, bovine, and other serum albumins.
It is thought that one of the major functions of serum
albumin is the transport of fatty acids and other long
chain anions. Since long chain fatty acids are highly 
insoluble at physiological pH it is, therefore, necessary 
that they should be strongly bound by serum albumin.
Table 1.2 lists some binding data for organic anions 
binding with human, and with bovine, serum albumin.
Sites for binding fatty acids are probably hydro- 
phobic clefts into which the aliphatic chains are inserted. 
In affinity chromatography, albumin attaches to the "tail" 
of palmitate^^ or other hydrocarbons^^ which have been 
immobilised on agarose.
It also appears that for a series of long chain anions 
possessing the same length of hydrophobic tail, their 
affinity for serum albumin increases as the polar end
group goes from OH to COgH to to S0^“ .
1.4.3. Anionic drugs
Binding studies of drugs to albumin have been exten-
8 5sively reviewed by Goldstein , and more recently by 
Meyer and Guttman^^ and Vallner^Z
Despite the size of the literature on the subject, 
a great part of this is qualitative or semi-quantitative.
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Anion Serum
albumin pH K /mol
1 3
” dm n^ Refs
Oleate Human 7.4 2 .6 X
8
1 0 1. 69
Oleate Bovine 7.45 8 .0 X lo" 2 70
8 .0 X 1 0 * 5
Palmitate Human 7.4 6 .2 X lo" 1 69
Palmitate Bovine 7.45 6 .0 X lo' 6-7 70
3 .0 X 1 0 *
Linoleate Bovine 7.4 1 .3 X 1 0 ^ 2 70
2 .5 X
6
1 0 5
Stearate Bovine 7.45 1 .1 X 1 0 2 70
4 .0 X 1 0 5
Tetradecanoate Bovine 7.45 4 .0 X 1 0 * 7-8 70
1 .4 X 1 0 *
Dodecanoate Bovine 6 . 8 2 .3 X 1 0 * 6-7 71
1 .6 X 1 0 * 2 70
2 .4 X 1 0 * 5 70
Decanoate Bovine 6 . 8 6 X 1 0 ^ 6-7 71
Octanoate Bovine 6 . 8 5 X lo"" 4-5 71
Bilirubin Human 7.4 1 X 1 0 * 1 72
7.4 7 X lo’ 1 73
Hematin Human 7.5 5 X lo’ 1 74
L-thyroxine Human 7.4 1 .6 X 1 0 * 1 75
L-ttyptophan Human 7.4 1 .6 X lo"" 2 76
Estradiol Human 7.4 1 .0 X 1 0 * (1 ) 77
Progesterone Human 7.4 3 .7 X lo"" (1 ) 77
Cortisol Human 7.4 5 .0 X 1 0 * 2 78
Corticosterone Human 7.4 1 .3 X lo"" (1 ) 78
Aldosterone Human 7.4 <5 X 1C
3
(1 ) 79
Testosterone Human 7.4 4 .2 X 1 0 * (1 ) 80
Prostaglandin Human 7.5 7 .0 X 1 0 * 2 81
Urate Human 7.4 3 .0 X 1 0 ^ (1 ) 82
Parenthesis mean that n = 1 was assumed.
Table 1.2 Binding data for some organic anions.
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It is common for the percentage of a drug bound to 
albumin to be quoted. This is misleading since the per­
centage bound is dependent on protein and drug concentra­
tions. Even when binding constants have been determined 
for drug-albumin interactions, it is usual to assume a 
single binding site model, which appears from the work done 
here to be an erroneous assumption. In cases where the 
binding properties of the same substance have been studied 
by different workers, values of constants frequently vary 
widely.
Nevertheless it appears that albumin has a strong 
affinity for most anionic drugs, in some cases the affinity 
is so strong that little of the drug exists as the unbound 
species. Table 1.3 lists a few examples of drug-albumin 
interactions.
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Compound Primary affinity^ constant mol^^dm
N o . of 
Sites Ref.
Sulphadiazene 3.6 X 10^ 1 88
Sulphisomidine 5.0 X 10^ 1.1 89
Sulphathiazole 2.96 X 10^ 2.0 90
Salicylate 4.0 X 10^ 1 91
2.19 X 10^ 4 92
Warfarin 2.20 X 10^ 2 93
1.4 X 10^ 1 94
6.5 X 10^ 2.0 95
Phenylbutazone 2.7 X 10^ 2 98
4.4 X 10^ 0.8 95
Oxacillin 4.7 X 10^ 1 96
Penicillin G 1.1 X 10^ 1 97
Ampicillin 5.0 X 10^ 1 96
Carbenicillin 2.0 X 10^ 1 96
Tolbutamide 4.1 X 10^ 1.4 99
Chlorpropamide 1.09 X lO"^ 1.64 99
Table 1.3. Binding data for some anionic drugs 
with human serum albumin.
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1.4.4. Anionic Dyes
Numerous, anionic dyes have been studied for their 
interaction with blood proteins. Of these the azo-dyes 
are probably the most widely investigated group. In addi­
tion to those azo-dyes previously mentioned, Karush^^^, has 
studied binding of Methyl Orange"to bovine serum albumin 
by partition analysis and dialysis. He obtained Scatchard 
data (see p45) for the dye protein system. Klotz and 
Luborsky^^^ studied the effect of adding Glycine or 
6 -Alanine to solutions containing Methyl Orange or 
p-aminoazobenzene, and bovine serum albumin. They found 
that addition of the amino-acids increased binding. They 
attributed this to both an increase in the dielectric 
constant of the solution and a specific interaction of 
the added amino acid.
Burkhard^^^ conducted some competition experiments 
between Methyl Orange, anthranilic acids and bovine serum 
albumin, and between Methyl Orange, p-aminobenzoic acid 
and bovine serum albumin. He found that the anthranilate 
ion was more effective than the p-aminobenzoate ion in 
displacing Methyl Orange from protein surfaces.
Klotz et al.^^^ carried out some spectrophotometric 
and dialysis experiments with a range of azo-dyes. These 
included Methyl Orange, Ethyl Orange, Propyl Orange, Butyl 
Orange, Methyl Red, ortho and para Methyl Red (fig.1.17)
4'-dimethylaminoazobenzene-3-phosphonate, 4'-dimethyl- 
aminoazobenzene-4-phosphonate and 4 'dimethylaminoazo- 
benzene-4-arsonate. From these studies it appeared that 
'optical displacement is a measure of degree of binding' 
although this statement is not necessarily true in all
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cases, (see Ch.8 )
104The same group of workers measured the relative 
binding of Methyl Orange, Methyl Red, para Methyl and 
meta Methyl Red to bovine and human albumin. In all cases 
they observed greater binding to human albumin than to 
bovine albumin.
Karusch^^^ has also studied, by dialysis, the binding 
of p-(2-hydroxy-5-methylphenylazo)-benzoic acid for which 
he proposed at 25°C, a two binding site model. He found 
the primary affinity constant to be 6.15 x 1 0  ^ mol”^ dm^ 
and the number of primary binding sites per molecule to 
be 4.66. The secondary sites (17.34 per molecule) had a 
binding constant of 1.90 x 10^ mol”^ dm^. He also showed^^^ 
that the same dye competes with dodecyl sulphate in its 
reaction with bovine serum albumin.
Burkhard et al.^^^ showed that binding of 4'-amino 
benzene-4-sulphonate increased if the amino nitrogen was 
alkylated, or the amino group removed.
108French and Pritchard showed that the spectral 
shape of dimethyl-p-aminoazobenzene depends on the buffer 
used, and also observed no spectral change on addition of 
bovine fibrinogen fraction I or bovine plasma albumin.
109Uzman showed that Methyl Orange binds more strongly 
to bovine serum albumin denatured with urea and guanidine 
hydrochloride, than to native protein.
A polarographic method for studing the binding of 
Evans Blue with rabbit plasma has been used^^^, and dye 
binding curves have been produced.
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1.5 Data Plotting
Many ways of presenting binding data have been suggested
111The Langmuir isotherm is one such approach.
Consider the reaction between a drug (D) and a single 
class of binding site on the protein (S).
D + S = DS 
The association constant K is given by 
K = [DS] (1.1)
[d ][sj
Let the total concentration of sites be and the
fraction of sites bound be 0
Therefore [DS] = [S.^.]0tot
[S] = (1 - 8 )[Stot]
K[D] = 0 ( 1 +  K[D])
hence 9 = K[D]
1 + K [Dl
The Langmuir isotherm is, therefore, a curve which 
approaches a straight line, gradient K as the free drug 
concentration approaches zero.
.0
0
0
[D]
Fig. 1.14 Typical Langmuir isotherm
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Much better approaches to the problem are provided 
by reciprocal, Klotz or Scatchard plots.
Reciprocal plots
From equation (1.1) and the relationship that 
[s] = - [DS]
K = [DS]
[D]([S^Q^]-[DS])
1 [D]([ S . ] - [ D S ] )
K =______  tot________
Cd s ]
(1 .2)
^  = [D][S^_^]/ 1
^°^^(tïïs] -[s ^ , ]
 ^ "[4 ,] =[dI] (1.3)
Since [S. .] is not known usually it is assumed that [S. .]tot tot
is proportional to the total albumin concentration [P]
thus [S^Q^] = n [P] (1.4)
n is, therefore, the number of sites per albumin molecule
if [s. .] and [P] are in the same units,tot
Substituting 1.4 into 1.3.
1 1 1 1 ct
ïïk- lD][p] + FTP] = I d s ] (I'S)
Thus at constant albumin concentration a plot of 1/[DS] 
versus 1/[D] gives a straight line, gradient l/nK[P] and 
intercept l/n[P].
Slope
l/nk[P]
[DS]
1 /n
1/
Fig. 1:15
Typical reciprocal 
plot
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Alternatively with non constant albumin concentrations,
a plot of [P]/[DS] versus 1/[D] gives a line of gradient
1/nk intercept 1/n. This form of plot is known, usually
41as a Klotz plot
Scatchard Plots 112
From equation (1.5)
1 . 1  - 1  
nk T d ][P] n[P]
1 . [DS] . [DS] =
nk T dTT p ] nTPl
[DS] . [DS]
T dTTp ] = nk -
1
T d s ]
K
Thus a plot of [DS]/[P] (often called r), versus 
r/[D], gives a straight line, intercept nk and gradient 
—k .
nk
[D] Slope = -K
r
fig.1.16 Typical Scatchard plot
1 .6 Objectives of this investigation
The objectives of this investigation were:
a) To develop a reliable, single phase technique to
study the interactions between human serum albumin 
and organic anions.
b) To use the method to study a series of related com­
pounds, and to correlate structural features of
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the compounds with their binding characteristics.
c) To confirm these binding characteristics by means of
a conventional multiphase method for measuring the 
binding of anions to proteins (ultrafiltration).
d) To develop a single phase method to study competitive
interactions between anions and human serum albumin.
e) To correlate competitive studies with the single
ligand binding studies.
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CHAPTER 2
EXPERIMENTAL TECHNIQUES
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2.1. Materials
2.1.1. Buffer solutions
AnalaR potassium dihydrogen orthophosphate, and diso- 
dium hydrogen orthophosphate were purchased from B.D.H. 
Chemicals Ltd. Ail solutions used in this study were made 
up in phosphate buffer, pH 7.4, consisting of 0.05334 mol 
dm"3 Na2 HP0 ^.1 2 H2 0  and 0.01334 mol dm"^ KH2 P0 ^.^^^ The 
buffer solutions were always filtered prior to use, stored 
in the refrigerator, and never kept for more than a week.
2.1.2. Proteins
Human serum albumin, Cohn fraction V, human albumin, 
crystallised lyophilised and essentially globulin free, 
(H.S.A.C.L.E.G.F.), and bovine serum albumin, Cohn fraction 
V, were all purchased from the Sigma Chemical Company.
Protein solutions were made in the following way:- 
To avoid frothing, the buffer solution was added to a pre­
viously weighed portion of the crystalline material, slowly 
and down the side of the weighing vessel. The solution was 
allowed to stand for approximately twenty minutes to allow 
dissolution of the protein. The solution was then gently 
agitated to ensure mixing. If further dilution was necessary 
the contents of the vessel were poured slowly down the side 
into a volumetric flask, and made up to volume with buffer 
solution, always adding further buffer in a way so as to 
prevent frothing. Mixing was achieved by gentle agitation 
of the flask. Protein solutions were never used after two 
days.
2.1.3. Dyes and pharmaceuticals
Methyl Orange 1, Mordant Yellow 12, Mordant Yellow 7 
and Mordant Yellow 10, were purchased from the Aldrich
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Chemical Company Inc. 5-phenylazosalicylic acid and 
4-hydroxyazobenzene-4'-sulphonic acid were supplied by the 
Alfred Bader Library of Rare Chemicals, a division of the 
Aldrich Chemical Company Inc. Bromophenol Blue and azo- 
benzene were obtained from B.D.H. Chemicals Ltd., and Evans 
Blue from Hopkin and Williams Ltd. Warfarin was purchased 
from the Sigma London Chemical Company.
Sulindac was a gift from Merck, Sharpe and Dohme.
M.T.T. was donated by the Wellcome Research Foundation.
None of these compounds were further purified.
In addition two further dyes. Alizarin Yellow GG and 
4-azobenzenesulphonic acid were synthesised according to 
the procedures described below.
All the dyes and pharmaceuticals were found to obey 
the Beer-Lambert law over the concentrations used.
1142.1.4. Synthesis of 4-azobenzenesulphonic acid trihydrate.
  H-SO. (fuming)
Azobenzene (lOg) was pulverised by grinding in a mortar.
3 —330cm of fuming sulphuric acid was placed in a 100cm round
bottomed flask equipped with an efficient stirrer. The
powdered azobenzene was added slowly with stirring, and each
portion was allowed to dissolve before the next was added.
The temperature of the reaction mixture was maintained below
50°C. The addition of the azobenzene required about thirty
minutes. The mixture was then heated on a steam bath at
75°-80°C for 5 minutes. The mixture was cooled to 50°C. and
3poured slowly with vigorous stirring onto 150cm of ice.
30cm^ of concentrated HCl was added to the hot solution and
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the mixture cooled and refrigerated overnight. The orange 
crystals of 4-azobenzenesulphonic acid were filtered on a 
Buchner funnel. The filtration was very slow. The preci­
pitate was sucked as dry as possible, and whilst still moist
was dissolved in 30 cm^ of hot water. The solution was
3 3filtered, and 30cm of 95% ethanol and 30 cm of concen­
trated HCl were added to the filtrate. The mixture was 
cooled overnight in the refrigerator. The precipitate was 
filtered and washed with a cold mixture of 1 0  cm^ each of 
water, alcohol and concentrated HCl, and then air dried.
The dry acid was dissolved in the minimum quantity 
of hot ethyl acetate and the solution filtered and cooled 
in the refrigerator overnight. The precipitate was filtered 
and re^^-crystallised from the minimum quantity of a mixture 
containing 30% ethanol, 30% water and 40% concentrated HCl.
The product was obtained in a yield of 53.2% and its 
purity checked by its melting point of 127-129°C_ (literature 
value = 127°C^^^), and an elemental analysis for nitrogen, 
carbon and hydrogen. (N = 9.0%, C = 45.4%, H =» 5.0%, the 
theoretical composition is:- N=8.85%, C = 45.5% and H = 
5.06%).
2.1.5. Synthesis of Alizarin Yellow GG
- S - * ” Cl
N o W  o-5°G
COoH
2mol dm 
\__ / 0 - 10°C
NO
N=N ■OH
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3-nitroaniline was suspended and heated with a mixture
3 3of concentrated HCl (25cm ) and water (25cm ) to form a
fine suspension of the hydrochloride. This was then cooled 
quickly in an ice-salt mixture and a solution of sodium 
nitrite (7.0g) in water (15cm^) was added dropwise over 
15 minutes, keeping the temperature at 0-5°G. Stirring 
was continued for a further 30 minutes, keeping the tempera­
ture at less than lO^C. The filtered, cold, solution was
then added to a solution of salicylic acid (14g) in 2 mol
— 3 3dm” sodium hydroxide (100cm ) containing crushed ice (150g).
The dye was liberated by the addition of concentrated HCl.
The yellow crystals were filtered on a Buchner funnel and 
washed with concentrated HCl. The product was then re­
crystallised by dissolving in the minimum quantity of hot 
ethyl acetate, filtering and then cooling. The re­
crystallisation was repeated twice. The product was ob­
tained in a yield of 27.8%.
The infrared spectra of the acid and sodium salt was 
compared with Aldrich standard spectra, and the product 
analysed for nitrogen, carbon, and hydrogen (N = 14.9%,
C = 54.1%, H = 3.1%, the theoretical composition is:- 
N = 14.64%, C = 54.37%, H = 2.79%).
2.2. Experimental methods
2.2.1. Method 1 . Spectrophotometric titrations
All absorption spectra were measured using a Perkin 
Elmer 555 U.V/visible spectrophotometer, using a slit width 
of 1.0 nm . The cell compartments were electrically thermo­
stated at 21.0°C(io.l°C) using a Perkin Elmer C550-0555 
Peltier type thermostat.
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Clean, dry Helma 'Tandem' spectrophotometric cells 
(path length of each compartment = 0.4375 cm) were initially 
balanced in the spectrophotometer by performing a background 
correction over the wavelength range to be measured.
1 cm^ of dye solution was placed in one of the sample 
compartments whilst the remaining sample compartment, and 
those of the reference cell, were filled with 1 cm^ of buffer 
solution. (The contents of the buffer filled compartment 
of the sample cell and the corresponding compartment of the 
reference cell were left unaltered throughout the course of 
the experiment.)
The U.V/visible absorption spectrum was then measured 
over the required wavelength range. Absorption measurements 
were recorded on a printer sequencer (Perkin Elmer PRS-10) 
at lOnm intervals over the described wavelength range.
3 3
0 . 0 1  cm of a stock albumin solution and 0 .0 1 cm of
a dye solution of twice the sample strength were added to 
the sample cell by means of a micropipette. O.Olcm^ of 
the albumin solution and 0 . 0 1  cm^ of buffer solution were 
added to the reference cell. The contents of each cell was 
stirred by means of a separate Pasteur pipette. The same 
pipette was kept for each cell throughout the course of the 
titration, thus minimising losses from the cell.
A number of similar increments were performed. By 
this method the total dye concentration during each titra­
tion was maintained at a constant value.
The following spectrophotometric titrations were 
performed by Method 1:
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Method 1.1:- Bromophenol Blue with H.S.A. fraction V
Dye concentration = 4.174 x lO”^ mol dm”^
-4Stock protein concentration = 2.899 x 10 
mol dm”^
Number of protein increments = 12
Method 1.2:- Methyl Orange with H.S.A. fraction V
Dye concentration = 1.515 x lO”  ^ mol dm“^
Stock protein concentration = 1.449 x lO”  ^
mol dm”^
Number of protein increments = 17
Method 1.3:^ Methyl Orange with B.S.A. fraction V
-4 -3Dye concentration = 1.515 x 10 mol dm
Stock protein concentration = 1.449 x lo”^
mol dm”^ I
Number of protein increments = 7. '
In addition, two further increments were made but using 
a O.lcm^ micropipette.
Method 1.4:- Warfarin with H.S.A. fraction V
-4 -3Dye concentration = 1.911 x 10 mol dm
Stock protein concentration = 1.449 x lo”^
_  2
mol dm”
Number of protein increments = 9
Method 1.5:- Evans Blue with H.S.A. fraction V
Dye concentration = 7.183 x lO”  ^ mol dm”^
-4Stock protein concentration = 7.247 x 10
— 3mol dm”
Number of protein increments = 10
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Method 1.6:- Evans Blue with H.S.A. fraction V
Dye concentration =-7.183 x 10~^ mol dm”  ^
Stock protein concentration = 2.899 x lo”  ^
mol dm”^
Number of protein increments = 10 
Method 1.7:- Evans Blue with H.S.A. (C.L.E.G.F.)
Dye concentration = 7.748 x lO”  ^ mol dm”  ^
Stock protein concentration = 8.015 x lO”  ^
mol dm”^
Number of protein increments = 1 4 .
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Method 1.8 Mordant Orange 1 with H.S.A. (C.L.E.G.F.)
Method Dye concentration 
/lO”  ^ mol dm”
Stock protein 
concentration? 
/lO mol dm
Number of 
incre­
ments
1 .8 a 0.7792 3.672 14
1 .8b 0.7792 3.672 14
1 . 8 c 1.558 7.354 14
1 .8d 1.558 7.334 14
1 . 8 e 2.460 7.319 14
1 .8 f 2.445 7.280 14
Method 1.9 Mordant Yellow 12 with H.S.A. (C.L.E.G.F.)
Method Dye concentration /1 0 - 4  mol dm-3
Stock protein 
concentration. 
/lO” mol dm”
Number of 
incre­
ments
1. 9a 2.397 7.944 14
1.9b 2.394 8.116 14
1.9c 3.586 7.749 14
1.9d 3.586 7.725 14
1.9e 5.405 7.341 14
1.9f 5.382 7.464 14
Method 1.10 Alizarin Yellow GG with H.S.A. (C.L.E.G.F.)
Method Dye concentration /lo” mol dm
Stock protein 
concentration^ 
/lO mol dm”
Number of 
incre­
ments
1 .1 0 a 1.508 7.833 1 0
1 .1 0 b 1.679 3.819 1 0
1 .1 0 c 1.673 3.819 1 0
l.lOd 1.401 3.819 1 0
l.lOe 1.410 3.819 ' 1 0
l.lOf 1.059 3.819 1 0
l.lOg 1.055 3.819 1 0
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Method 1.11 Mordant Yellow 7 with H.S.A. (C.L.E.G.F.)
Method Dye Concentration /lo” mol dm
Stock protein 
concentration
/10“4 mol dm”3
Number of 
incre­
ments
1 .1 1 a 1.578 7.465 5
1 .1 1 b 1.584 7.536 5
1 .1 1 c 2.292 7.552 5
l.lld 2.295 7.536 5
l.lle 2.840 7.377 5
l.llf 2.854 7.377 5
Method 1.12 5-phenylazosalicylic acid with H.S.A. (C.L.E.G.F.)
Method Dye concentration /IC mol dm
Stock protein 
concentration. 
/lO mol dm”
Number of 
incre­
ments
1 .1 2 a 1.096 7.265 5
1 .1 2 b 1 . 1 0 2 7.246 5
1 .1 2 c 1.494 7.326 5
1 .1 2 d 1.500 7.341 5
1 .1 2 e 1.806 7.333 5
1 .1 2 f 1.809 7.345 5
Method 1.13 4-azobenzenesulphonic acid with H.S.A. (C.L.E.G.F.)
Method Dye concentration /lo” mol dm”
Stock protein 
concentration? 
/lO” mol dm”
Number of 
incre­
ments .
1 .13a 0.8808 7.536 6
1.13b 0.8838 7.536 6
1.13c 1.164 7.493 6
1.13d 1.165 7.493 6
1.13e 1.499 7.420 6
1.13f 1.503 7.420 ■ 6
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Method 1.14 Mordant Yellow 10 with H.S.A. (C.L.E.G.F.)
Method Dye concentration /lO” mol dm
Stock protein 
concentration- 
/lO mol dm”
Number of 
incre­
ments
1.14a 1.285 7.312 5
1.14b 1.289 7.310 5
1.14c 1.664 7.449 5
1.14d 1.664 7.438 5
1.14e 2 . 1 1 2 7.328 5
1.14f 2.128 7.294 5
Method 1.15 4-hydroxyazobenzene-4'-sulphonic acid with
H.S.A. (C.L.E.G.F.)
Method Dye_concentration /lO” mol dm”
Stock protein 
concentration^ 
/lO” mol dm
Number of 
incre­
ments
1.15a 0.8881 7.694 5
1.15b 0.8964 7.710 5
1.15c 1.206 7.609 5
1.15d 1.213 7.632 5
1.15e 1.489 7.536 5
1.15f 1.502 7.536 5
Method 1.16 Bromophenol Blue with H.S.A. (C.L.E.G.F.)
Method Dye concentration /lO” mol dm”
Stock protein 
concentration_ 
/lO” mol dm”
Number of 
increM 
ments
1.16a 3.548 3.949 1 0
1.16b 3.565 3.949 1 0
1.16c 4.417 3.949 1 0
1.16d 4.415 3.949 1 0
1.16e 5.284 3.949 1 0
1.16f 5.297 3.949 1 0
5.8
Method 1.17 M.T.T. with H.S.A. fraction V
Method Dye concentration 
/lO mol dm”^
Stock protein 
concentration
/lO”  ^mol dm”^
Number of 
incre­
ments
1.17a
1.17b
6.130
3.065
2.899
2.899
5
5
Method 1.18 Sulindac with H.S.A. fraction V
Method Dye concentration 
/lO”  ^ mol dm”^
Stock protein 
concentration
/lO”  ^ mol dm”^
Number of 
incre­
ments
1.18a 1.998 2.898 7
1.18b 0.9989 2.898 7
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2.2.2 Method 2 Spectrophotometric titrations (competition
reactions)
The method used was essentially the same as that used 
in a normal spectrophotometric titration,(Method l), except 
that Icm^ of a mixture of Bromophenol Blue (^v4.400 x lO”  ^
mol dm ^ ) and the competing dye were placed in the sample 
beam. As well as the 0.01 cm^ of stock albumin solution,
0 . 0 1  cm^ of a solution containing double the concentration 
of Bromophenol Blue, and double the concentration of com­
peting dye were added to the sample cell. Thus the concen­
trations of both Bromophenol Blue and the competitor dye 
were maintained at a constant level throughout the course 
of the titration.
In each case the Bromophenol Blue spectrum was measured 
between 550 and 620 nm, and absorbances measured at 10 nm 
intervals. Ten increments of H.S.A. (C.L.E.G.F.) were made.
Method 2.1. Bromophenol Blue Mordant Yellow 10, competition
Method
Bromophenol Blue 
concentration 
/lO” mol dm”
H.S.A. stock 
concentration^ 
/lo” mol dm”
Competing dye 
concentration^ 
/lO mol dm
2 ,1 a 4.473 3.623 4.425
2 .1 b 4.442 3.623 4.425
2 .1 c 4.481 3.658 8.848
2 .Id 4.487 3.658 8.848
2 .le 4.418 3.658 17.70
2 .If 4.429 3.658 17.70
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Method 2.2. Bromophenol Blue - Mordant Yellow 12 competition
Method
Bromophenol Blue 
concentration 
/lO mol dm”^
H.S.A. Stock 
concentration 
/lO” mol dm”
Competing dye 
concentration 
/lO” mol dm”
2 .2 a 4.459 3.888 4.459
2 .2b 4.465 3.888 4.465
2 .2 c 4.437 3.888 8.852
2 . 2d 4.428 3.888 8.852
2 .2 e 4.432 3.859 17.70
2 .2 f 4.448 3.859 17.70
Method 2.3. Bromophenol Blue - 5-phenylazosalicylic acid
competition
Method
Bromophenol Blue 
concentration 
/lO mol dm”
H.S.A. Stock 
concentration 
/lO”  ^ mol dm”
Competing dye 
concentration 
/lO” mol dm”
2.3a 4.426 3.713 4.418
2.3b 4.412 3.713 4.418
2.3c 4.440 3.713 8.836
2.3d 4.396 3.713 8.836
2.3e 4.404 3.903 2 . 0 0 2
2.3f 4.382 3.903 2 . 0 0 2
Method 2. 4. Bromophenol Blue - 4-azobenzenesulphonic acid
competition
Method
Bromophenol Blue 
concentration 
/lO” mol dm”
H.S.A. Stock 
concentration 
/lo” mol dm”
Competing dye 
concentration 
/lo” mol dm”
2. 4a 4.454 3.733 5.005
2.4b 4.396 3.733 5.005
2.4c 4.385 3.733 1 0 . 0 1
2.4d 4.385 3.733 1 0 . 0 1
2. 4e 4.415 3.903 2 0 . 0 2
2.4f 4.421 3.903 2 0 . 0 2
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Method 2.5. Bromophenol Blue - Mordant Yellow 7 competition
Method
Bromophenol Blue 
concentration 
/lO” mol dm”^
H.S.A. Stock 
concentration 
/lo”  ^ mol dm“^
Competing dye 
concentration 
/1 0 ~ mol dm”
2.5a 4.465 3.835 4.433
2.5b 4.489 3.835 4.433
2.5c 4.437 3.835 8.867
2.5d 4.443 3.835 8.867
2.5e 4.440 3.835 17.73
2.5f 4.434 3.835 17.73
Method 2.6. Bromophenol Blue - Mordant Orange 1 competition
Method
Bromophenol Blue 
cohcehtration 
/lO”  ^ mol dm”^
H.S.A. Stock 
concentration 
/lO”  ^ mol dm”^
Competing dye 
concentration 
/lo” mol dm”
2 . 6 a 4.445 3.675 4.435
2 .6b 4.448 3.675 4.435
2 .6c 4.468 3.675 8.871
2 .6d 4.448 3.675 8.871
2 . 6 e 4.476 3.661 17.74
2 .6 f 4.465 3.661 17.74
Method 2. 7. Bromophenol Blue - Alizarin Yellow GG competitio
Method
Bromophenol Blue 
concentration 
/lO”  ^ mol dm”^
H.S.A. Stock 
concentration 
/lO  ^ mol dm”^
Competing dye 
concentration 
/lO” mol dm”^
2.7a 4.415 3.849 4.263
2.7b 4.423 3.849 4.263
2.7c 4.390 3.788 8.525
2.7d 4.437 3.788 8.525
2.7e 4.398 3.788 17.05
2.7f 4.432 3.788 17.05
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Method 2.8. Bromophenol Blue with 4-hydroxyazobenzene-4*- 
sulphonic acid competition
Method
Bromophenol Blue 
concentration 
/lO mol dm”
H.S.A. stock 
concentration 
/lO” mol dm”
Competing dye 
concentration
/lO”  ^ mol dm ^
2 .8 a 4.438 3.848 4.418
2 .8b 4.415 3.848 4.418
2 .8c 4.434 3.743 8.835
2 .8d 4.434 3.743 8.835
2 .8e 4.418 3.743 17.67
2 .8 f 4.426 3.743 17.67
2.2.3. Method 3 . Bromophenol Blue - Sulindac competition 
As for Method 2 , but using H.S.A. fraction V and only 
seven increments of the protein.
Bromophenol Blue concentration = 4.180 x lO”^ mol dm”  ^
Stock albumin concentration = 2.899 x io”  ^ mol dm”^
Sulindac concentration = 4.050 X  10  ^ mol dm ^
2.2.4. Method 4 . Interaction of M.T.T. with H.S.A.
fraction V
Using the same instruments and conditions aa described 
for Method 1, Icm^ of pH 7.4 buffer solution were placed in 
the sample beam and reference beam. A baseline correction 
was performed over the wavelength range 250-400nm. To the
sample cell was added O.Olcm^ of a solution containing
— 3 — 3 3
1.799 X  10“ mol dm” of the drug and 0.01cm of buffer
solution. The spectrum was measured over the described
wavelength range. Seven further increments of the drug were
made. The experiment was then repeated using solutions
containing H.S.A. fraction V at concentrations of 5.798,
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2.899 and 1.449 x 10  ^ mol dm”  ^ in the sample and reference 
cells. O.Olcm^ of double concentration albumin was added 
to the sample beam on addition of the drug to maintain the 
albumin concentration.
2.2.5. Method 5 . Ultrafiltration rejection curve for
Evans Blue
An Amicon UMIO filter was soaked in distilled water 
for one hour as recommended by the manufacturer. This was 
then placed in an Amicon ultrafiltration cell, model 12, 
maintained at 21°C in a thermostated room. 10 cm^ of Evans
f
— 5 — 3Blue <1.192 X  lO” mol dm” ) were placed in the cell and
about 5 cm^ run off under a pressure of 5 p.s.i. of Nitrogen
('white spot' supplied by the British Oxygen Company). This
was repeated twice to ensure equilibration. A further 10 cm^
of dye were added to the cell and approximately 0.75 cm^
fractions collected as they passed through the filter.
Simultaneously 0.5 cm^ fractions were collected from the
interior of the cell. These fractions were diluted, their
absorbance measured at 6 0 2 nm, and the concentration of the
— 1 2solutions calculated (e602 = 4398 mol” m ). The experiment 
was repeated, and then repeated again , using 2.384, 3.576, 
4.768 and 5.960 x lO”  ^ mol dm”  ^ Evans Blue solutions. A 
rejection curve was thus obtained (curve (a)(p 164).
A solution of H.S.A. (C.L.E.G.F.) (1.449 x 10  ^ mol
dm”^) was then passed through the filter. This process was
repeated, and then Evans Blue solutions were ultrafiltered
as described above. In this case one further Evans Blue
— 5 — 3solution of concentration 8.344 x 10 mol dm .was used.
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2.2.6. Method 6. Ultrafiltration of Azo-dyes with H.S.A.
An Amicon YM 10 filter was soaked in distilled water 
and placed in the ultrafiltration cell. lOcm^ of the 
azo-dye/protein solution being studied were placed in the 
cell and approximately Icm^ run off under pressure as des­
cribed in Method 5. Collection of this fraction required 
about 10 minutes. This fraction was discarded. The con­
tents of the cell were removed and a further lOcm^ of dye/ 
protein solution added to the cell and 1 cm^ ultrafiltered 
as before. The collected fraction was diluted to give a 
suitable absorbance at the wavelength of maximum absorbance 
and its absorbance measured. This process was repeated 
twice and then the whole experiment repeated with further 
azo-dye/protein mixtures. In this way the concentrations 
given in Chapter 6 were calculated (p 169-181).
2.3. Computation
All data was processed using programmes written in 
Fortran IV and run either on the University of London 
Computer Centre C.D.C. 7600, or on a VAX 11 Computer.
2.3.1. Matrix rank analysis
The matrix rank analysis programme, based on the 
method of Wallace and Katz^^^ is reproduced in appendix 1.
2.3.2. U.V./visible spectrophotometric data fitting
The programme employed two 'packaged' sub-routines.
The first of these was a routine for obtaining roots of 
polynominals by Newton's method (Nottingham Algorithms Group 
C02AEF) based on publications by Adams, Grant and
Hitchins^l^'ll^"
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The second was a data 'best fit' package (C.E.R.N.
Computer Centre 'Minuits'). The package used three data
fitting techniques. The first of these used a Monte-Carlo
search for the best minimum. The second ('Migrad') performed
a local function minimisation using Fletchers "Switching"
119variation of the Davidson-Fletcher-Powell algorithm.
The third ('Simplex') performed a simplex minimisation 
by the method of Nelder and Mead.^^^
The programme is reproduced in appendix 2.
2.3.3. Ultrafiltration data fitting
Binding parameters were obtained from ultrafiltration 
data using a simplex fitting r o u t i n e . C u b i c  equations 
were solved using the subroutine 'cubic'. The ultrafiltra­
tion data fitting routine is reproduced in appendix 3.
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CHAPTER 3
THE
APPLICATION OF MATRIX RANK ANALYSIS 
TO THE SPECTRA OF 
ANIONIC LIGAND - SERUM ALBUMIN INTERACTIONS
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3.1 . Theoretical
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Fig.3.1. Sketch of spectral changes in a dye 
spectrum accompanying dye-protein 
interactions.
Consider a series of solutions' containing two light 
absorbing species at a wavelength X^. The absorbance of
the ]th solution, per unit pâthlength is given by
^ij " ^il ^ij ^i2 ^ 2 j 
where = the absorbance of the jth solution at the
ith wavelength
\ l  ~ extinction coefficient at the ith wave­
length of the 1 st component
^±2 ~ the extinction coefficient at the ith wave­
length of the 2 nd component
C ^ . = the concentration of the 1st component in 
-L]
the jth solution
C2 j = the concentration of the 2 nd component in 
the jth solution.
Consider now the absorbance of two solutions at two wave­
lengths. These can be written:-
^11 = =11 ^11 + =12 ^21
A21 = =21 ^11 + =22 '^21
Ai 2 = =11 ^12
+ =12 ^22
^22 ^ =21 ^12 + = 22 ^22
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It is a known property of simultaneous linear equations 
of this type that the determinant of a matrix of the 
absorbances is equal to the product of the determinants 
of the corresponding extinction coefficient and concentra­
tion matrices.
Thus :-
* 1 1 * 1 2 ^ 1 1 ^ 1 2
X
^ 1 1 ^ 1 2
* 2 1 * 2 2 ^ 2 1 ^ 2 2 ^ 2 1 ^ 2 2
since all e. . and . have finite values, the determinant
of the absorbance matrix will be greater than zero, and 
given by
(*11 *22 ”  *21 * 12  ^ ^  (=11 =22 " ^ 2 1 ^ 12^(^11 ^22 "  ^21 ^12 
Now consider the solutions to contain three species, but
that the concentration of the third species is zero. The
absorbance of any solution will be given by:-
*ij ^ =il ^Ij ^i2 ^2 j ^i3 ^3j
^ ^il ^Ij ^i2 ^2j =i3'0
for a 3 X 3 matrix, then, the corresponding determinants
will be given by:-
* 1 1 * 1 2 *13 =11 = 1 2 =13 ^ 1 1 ^ 1 2 ^13
* 2 1 * 2 2 *23 =21 = 22 = 23 X ^ 2 1 ^ 2 2 ^23
*31 *32 *33 =31 =32 = 33 0 0 0
the concentration matrix determinant is given by:- 
^ 1 1  ( ^ 2 2 * ^  " C 23'0 ) - ^ 1 2  ( ^ 2 1 * ^  ^ 2 3 . 0 )  +  C^ 3
(C2 1 .O - Cgg'O)
and is thus equal to zero.
In this way it may be seen that the determinant of a 3 x 3 
absorbance matrix for a system containing two species is zero. It
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may also be seen that the determinants of matrices of all 
higher orders will also be zero.
In the general case, therefore, for solutions contain­
ing n species, the determinant of the absorbance matrix of 
order n + 1 should reduce to zero, since the non-existent 
(n + 1 )th species always introduces a row of zeros into the 
concentration matrix.
Using similar reasoning it can also be seen that solu­
tions containing a non-absorbing species will give an 
absorbance matrix with rank equivalent to the number of 
absorbing species.
In reality, however, there is a limit(s) on the accuracy 
to which absorbances can be measured, so that
A — A , j Sobserved -
This error must be considered when considering whether a 
determinant is really zero.
Wallace and Katz^^^ have described a method for matrix 
rank analysis of absorbance spectra.
The method consists of setting up in addition to the 
absorbance matrix A, a companion matrix S, whose elements 
are the estimated errors of A^j. A is then reduced by 
a series of elementary operations to an équivalant matrix 
whose elements below the principal diagonal are all zero.
S is also continually transformed during the reduction of A 
by computing new values of based on the propagation of
errors in transforming A. The rank of A is then found from 
the number of non zero rows in the reduced matrix. An element 
in the A matrix is considered to be zero when it falls to a 
value lower than the equivalent value in the S matrix.
The A matrix is pivoted by an interchange of rows and
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columns to place the element whose absolute value is the 
largest in position 1.1, S is transformed by the same row - 
column interchanges used in A. The resulting A matrix is 
transformed to A' by the operation
*'i'l ” *ij “ (3.1)
^ 1 1
performed on all except the first row.
This operation makes all elements in the first column
identically zero except for the first one. S is transformed
1 2 1to S' by the equation for the propagation of errors in 3.1.
^'ij
' * 1 1  ' * 1 1  / .
2 (3.2)
"
The submatrices formed by deleting the first row and column 
of A ' and S' are then treated similarly to give A'' and S'' 
and so on until all the elements of the transformed A matrix 
below the principal diagonal are identically zero. It is 
then only necessary to compare elements on the principal 
diagonal of the transformed A and S matrices to determine 
how many rows are statistically non-zero, and, therefore, to 
find the experimental rank.
The main reason for pivoting the matrix to place the 
largest * elements on the diagonal is to minimise the rate of
propagation of errors. With this arrangement the coefficients
2 2 2 of Sj,, S a n d  S^^ in equation 3.2 can never exceed 1,
and the value of an element in S' after an operation, there­
fore, cannot exceed twice the value of the largest of the 
elements in S that goes into its calculation. If the matrix 
A contains n rows and all the elements in the original S 
matrix are identical and equal to S^, the largest possible 
value of S in the reduced matrix will be 2^"^S^, but it will
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usually be much smaller.
3.2. Matrix rank treatment of Bromophenol Blue - H.S.A.
Spectra
Tables 3.1 and 3.2 show a typical analysis for Bromo­
phenol Blue with various concentrations of H.S.A. fraction 
V (experimental method 1.1).(fig.3.2)
Every element of the original S matrix was taken as 
0.003 and so is not reproduced here.
An element on the principal diagonal of the A matrix 
was taken to be definitely non-zero if it exceeded four 
times the corresponding S matrix element.
If an A matrix element on the diagonal exceeded, but 
was less than four times the corresponding matrix element, 
then this was taken to indicate the possible presence of 
a species.
Any A matrix element which did not exceed the corres­
ponding S matrix element was taken to have a value of zero.
The third element on the principal diagonal of the A 
matrix, for this example, has the value 0.047 whilst the 
corresponding S matrix element has the value 0.005. This 
firmly indicates the presence of 3 spectrophotometrically 
distinguishable species in solution. However, the fourth 
element has the value 0.007 which, being less than -the S 
matrix elements value of 0 . 0 1  firmly excludes the possibility 
of a fourth species.
The simplest model available to explain the presence 
of three species in solution would be one in which there 
are two classes of binding site on the albumin molecule.
Thus the three species consist of the free dye and two bound 
species of dye. The binding of the dye to the albumin sites
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Fig.3.2 Absorbance spectra for the Titration of Bromophenol 
Blue (4.174 x lO”  ^mol dm” )^ with H.S.A. fraction V
The albumin concentrations are as follows 
/10-5 mol dm"3 (i) o, (2 ) .2842, (3 ) .5573, (4) .8203,
(5) 1.073, (6) 1 .3 1 8, (7) 1.553, (8 ) 1.856, (9) 1.999, 
(1 0) 2 .2 1 1, (1 1) 2.415, (1 2) 2.613, (13) 2.807.
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may be represented in the following way:-
D + S ^ #  DS^ (3.3)
D + S g *  DS^ (3.4)
where = the free primary binding site
S2 = the free secondary binding site 
D = free dye
DS^= the primary dye site complex 
DS2 = the secondary dye site complex 
It is also assumed that the total concentration of the 
primary binding site is related to the concentra­
tion of albumin (P^^^) by the relationship
= "1 Ptot
where n^ is the number of sites per albumin molecule. 
Similarly: ^2 ^°^ “ ^2 ^ ^tot
If the concentration of D is large in comparison with both 
and $2 ^°^ equations 3.3 and 3.4 will lie almost en­
tirely to the right hand side.
Therefore [DS^] = Hi'P^ot “ ^2* ^ tot
assuming all three species to obey Beer's law, the absorb­
ance per unit path length of a solution will be given by:- 
A = e^[D] + e^[DS^] + e2 CDS2 ] (3.5)
where e^,E^ and ^  are the corresponding molar extinction 
coefficients for the three species, free dye, primary site 
bound dye, and secondary site bound dye.
Under the conditions of a large relative free dye con­
centration, i.e. at the beginning of the titration, equation 
3.5 can be written:-
A = e^[D] + ^l^l*-^tot^ ^2^2^^tot^
A = Sf[D] +
77
Since [DS^] = and [DS2 ] =
If ^^^bound^ the total concentration of the bound dye then
[Dbounj] = + « 2 ^tot
[Ptot^ = [Dbound]
(n^+n2
and hence
A = Cf[D] + ( V X J ^ i ^ l i ’tPbound^
(n ^ + n 2 )
let (e^n^ +E 2 n2 ) _ e 
"l+ " 2
then A = ^[D] +Cb[Dbound]
If at some point E^ = = e^
A = :;([D]+[Dbound]) ^ ' 6 )
Since [D] + ^^bound^^^ constant for this titration at low 
albumin concentrations all spectra should pass through a 
single (isosbestic) point. This is observed at 602 nm. 
Furthermore, at low albumin concentrations the spectra will 
appear only to be those of a two species system.
Table 3.3 shows the effect of considering only the 
first six solutions in the titration in the matrix rank 
analysis. The first two elements on the principal diagonal 
of the final A matrix are clearly non-zero. The third 
element has the value 0 . 0 1 0  which is only very slightly 
larger than the corresponding S matrix value of 0.009.
Consider now the situation as the total site concen­
tration becomes very large. Most of the dye will be bound 
in one of the complexes DS^ or DS2 . Further changes in 
spectra will arise as a result of transfer of dye from one 
site to the other. The absorbance per unit path length will 
be given by
A = G^[DS^] +
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ORIGINAL A MATRIX
wavelength/nm
Albumin A q-5
620 600 580 5 60 540 520
0 .396 1.376 1.277 .807 .543 .317
.2842 .490 1.331 1.180 .765 .516 .305
.5573 .573 1.300 1.098 .731 .493 .294
.8203 .635 1.271 1.030 .702 .474 .284
1.073 .693 1.252 .971 .677 .457 .276
1.318 .741 1.240 .923 .656 .442 .267
tu
O'
taO3
oD)3O
CD
FINAL A MATRIX
1.376 .396 1.277 .807 .543 .317
0 .384 -.228 -.071 -.047 -.019
0 0 .010 .007 .006 .004
0 0 0 .001 .000 .000
0 0 0 0 -.001 -.001
0 0 0 0 0 .001
FINAL S MATRIX
.003 .003 .003 .003 .003 .003
0 .004 .007 .005 .005 .004
0 0 .009 .007 .006 .005
0 0 0 .008 .009 .010
0 0 0 0 .009 .010
0 0 0 0 0 .023
Table 3*3 Original and final matrices for the first six solutions 
of the Bromophenol Blue (4.174 x 10*^ mol dm~^)
H.S.A. fraction V titration.
Each element of the original S matrix was taken as 0.003
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Again assuming overlap of the spectra, at the point of 
overlap an isosbestic point will occur.
In this example (Table 3.4) the final five solutions 
in the titration have very similar absorbances below 592 nm.
In this instance matrix rank analysis shows the definite 
existence of two species and the possible existence of a 
third since the third element on the principal diagonal of 
the A matrix has the value 0.014 whilst the third element 
of the error matrix has the value 0.008.
3.3 Matrix rank treatment of Methyl Orange - serum albumin 
spectra
The absorbance spectra obtained as a result of the inter­
action of a number of different compounds with albumin have 
been measured.
Klotz has reported that Methyl Orange shows rather 
different spectral changes with bovine (experimental method 
1.3) as compared with human (experimental method 1.2) serum 
albumin. Figs. 3.3 and 3.4 confirm this observation.
Matrix rank analysis of the human serum albumin. Methyl 
Orange system indicates the existence of at least three 
species and possibly four. Analysis of the last ten spectra 
shows only the existence of two species, giving rise to the 
isosbestic point at 442 nm.
Rank analysis of the bovine serum albumin/Methyl Orange 
spectra shows the existence of at least two species and the 
probable existence of a third.
Tables 3.6 and 3.7 summarise the results of the matrix 
rank analysis of various ligand protein interactions.
ORIGINAL A MATRIX
80
Albumin con­
centration 
/lO mol dm”
620
wavelength/nm 
600 580 560 540
1.999 0.821 1.245 0.855 0.622 0.414
2.211 0.815 1.258 0.864 0.624 0.415
2.415 0.794 1.266 0.867 0.626 0.412
2.613 0.821 1.271 0.852 0.612 0.406
2.807 0.828 1.279 0.843 0.619 0.401
>
tr
en
O
M
cr
OJ
D
o
m
FINAL A MATRIX
1.279 0.828 0.843 0.619 0.401
0.000 0.035 0.001 0.015 0.021
0.000 0.000 0.014 0.004 0.003
0.000 0.000 0.000 0.007 0.002
0.000 0.000 0.000 0.000 0.002
FINAL S MATRIX
0.003 0.003 0.003 0.003 0.003
0.000 0.006 0.006 0.005 0.005
0.000 0.000 0.008 0.007 0.007
0.000 0.000 0.000 0.016 0.015
0.000 0.000 0.000 0.000 0.019
Table 3.4 Original and final matrices for the final five solutions 
of the Bromophenol Blue (4.174 x 10~^ mol dm~^) H.S.A, 
fraction V titration
Each element of the original S matrix was taken as 0.003
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Fig. 3»3 Absorbance spectra for the titration of Methyl Orange 
(1.515 X 10~^ mol dm~^) with H.S.A. fraction V
The protein concentrations /lO”  ^mol dm"^ were as 
follows:-
(I ) 0 , (2) 1.421, (3) 2.787, (4) 4.101, (5) 5 .3 6 8,
(6) 6.587, (7) 7.764, (8 ) 8.899, (9) 9.996, (10) 11.05,
(I I) 1 2.0 8 , (1 2) 13.07, (13) 14.02, (14) 14.95,
(15) 16.46, (1 6 ) 17.57, (17) 18.39, (1 8) 19.18
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Fig. 3.4 Absorbance spectra for the titration of Methyl
Orange (1.515 x 10~^ mol dm~^) with bovine serum 
albumin
-5 -3The protein concentrations /lO mol dm are 
as follows:-
(1 ) 0 , (2 ) 1.421, (3) 2.787, (4) 4.101 (5) 5 .368, 
(6) 5.587, (7) 7.764, (8 ) 8.899, (9) 18.39,
(1 0) 25.41.
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3.4 SUMMARY OF MATRIX RANK ANALYSIS OF THE SPECTRA OF
VARIOUS
ANIONS WITH SERUM ALBUMIN
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3.5, Matrix rank analysis of Bromophenol Blue - H.S.A. 
spectra - in competition reactions.
In the presence of Sulindac, Bromophenol Blue shows no 
change in absorbance spectrum at wavelengths longer than 
450 n m , even at relatively high Sulindac concentrations 
{[Sulindac] : [Bromophenol Bluel'vlOO: 1 ) . However, the 
changes which occur in the absorbance spectrum of Bromo­
phenol Blue on addition of human serum albumin are not the 
same as those which occur in the spectrum in the absence 
of Sulindac. Thus comparing fig 3.2 and 3.5, it can be 
seen that for essentially the same Bromophenol Blue and 
albumin concentrations, different sets of spectra are ob­
tained in the presence and absence of Sulindac.
These differences between the sets of data in the 
presence and absence of Sulindac may be thought to arise as 
a result of competition between Sulindac and Bromophenol 
Blue for binding sites on the albumin molecule.
Sulindac appears to bind to a single site on the 
albumin molecule, since matrix rank analysis of Sulindac- 
albumin absorbance spectra shows a rank of 2 , indicating 
2 species present, a free and a bound species.
Bromophenol Blue appears to bind to two sites on the 
molecule since a matrix of absorbance spectra for this 
system has a rank of 3.
The reactions may be represented thus:-
D + DS^ (3.7)
B + BSi (3.8)
B +
= 2
BS2 (3.9)
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Fig. 3 .5 . Absorbance spectra for the titration of Bromophenol 
Blue (4.180 X  10  ^mol dm with H.S.A.
(fraction V) in the presence of Sulindac 
(4.050 X  10*"^  mol dm~^)
Albumin concentration /lO”  ^mol dm”  ^were as follows:
(1) 0, (2) .2842, (3) .5573, (4) .8203, (5) 1.073,
(6) 1.318, (7) 1.553, (8) 1.856
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where D = Sulindac
B = Bromophenol Blue
= the Sulindac-site complex 
BS^ = the primary Bromophenol Blue complex 
BS2 = the secondary Bromophenol Blue complex 
= the unbound primary site 
S2 = the unbound secondary site
In the presence of a large excess of Sulindac, equation 
3.7 will lie almost entirely to the right, the concentration 
of S^ will, therefore, be small, and the principal Bromo­
phenol Blue reaction will be that given by equation 3.9.
Under these conditions a matrix rank analysis of the Bromo­
phenol Blue spectra at wavelengths greater than 450 nm, on 
addition of human serum albumin, might be expected to behave 
as a single site system, and thus give a matrix of rank 2 .
Table 3.8 shows that although the system tends towards 
a two site system there is still some secondary site present 
which suggests interaction of Sulindac with both sites.
Matrix rank analysis data for competition reactions 
between various azo-dyes and Bromophenol Blue with human 
serum albumin are shown in Table 3.9.
ORIGINAL A MATRIX
92
Albumin con 
centration 
(lO"^mol dm” )^
600 580 560 540 520 500 480 460
0 1.400 1.233 .769 .508 .301 .199 .208 .375
.2842 1.423 1.192 .757 .497 .292 .197 .207 .377
.5573 1.415 1.176 .740 .484 .281 .191 .205 .373
.8203 1.435 1.161 .726 .468 .273 .186 .204 .381
1.073 1.443 1.132 .717 .464 .272 .186 .203 .374
1.318 1.465 1.113 .707 .456 .267 .183 .205 .374
1.553 1.458 1.075 .688 .442 .261 .178 .200 .374
1.856 1.478 .062 .676 .429 .250 .172 .199 .380
FINAL A MATRIX
1.478 1.062 .676 .429 .250 .172 .199 .380
0 .227 .129 .102 .064 .036 .020 .015
0 0 .010 .008 .003 .004 .001 -.000
0 0 0 .005 .002 .001 .001 -.003
0 0 0 0 .002 .001 .001 -.006
0 0 0 0 0 .003 -.002 .001
0 0 0 0 0 0 .002 -.001
0 0 0 0 0 0 0 .001
FINAL S MATRIX
.003 .003 .003 .003 .003 .003 .003 .003
0 .006 .005 .005 .004 .004 .004 .004
0 0 .008 .006 .006 .005 .005 .006
0 0 0 .006 .008 .006 .005 .006
0 0 0 0 .005 .006 .009 .006
0 0 0 0 0 .024 .014 .011
0 0 0 0 0 0 .013 .017
0 0 0 0 0 0 0 .020
Table 3.8. Original and final matrices for Bromophenol Blue 
(4.180 X  10”  ^mol dm“ )^ with H.S.A.(fraction V) 
in the presence of Sulindac (4.050 x 10 mol dm )
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Table 3.9 Matrix rank data for competition reactions between 
Bromophenol Blue and various azo dyes with 
human serum albumin (crystallised, lyophillsed 
and essentially globulin free).
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CHAPTER 4.
DEVELOPMENT 
OF A
SPECTROPHOTOMETRIC TECHNIQUE 
FOR THE MEASUREMENT 
OF THE
BINDING OF DYES TO BLOOD PROTEINS
96
4.1. Interaction of M.T.T. with H.S.A.
The changes which occur in the spectra of coloured 
compounds when they bind to proteins appeared to be a 
potentially useful means of studying these interactions, 
since such methods afe free from apparatus binding problems 
associated with dialysis, the most frequently used technique.
M.T.T. gives a weakly coloured, yellow, aqueous solu­
tion, with an absorbance maximum at 275nm with a shoulder 
at 295nm (fig.4.2). On addition of human serum albumin 
fraction V (experimental method 4) the absorbance at 295nm 
increases, giving a well defined peak rather than a shoulder 
(figs. 4.3-4-5). Spectra in which the drug concentrations 
remain constant (experimental method 1.17) were also re­
corded (fig. 4.6, 4.7).
It was initially thought that the new peak (xmax 295) 
was due to a very large movement of the main peak (Xmax 274) 
on binding of the drug to human serum albumin. Fig. 4.6 
and 4.7 clearly show, however, that on adding excess of 
albumin to the drug the peak at 274nm still remains, although 
moved slightly to 276nm.
On saturation the peak at 295nm assumes a steady ab­
sorbance value. Using the Klotz^^ interpretation of these 
spectra it is assumed that this represents the spectrum 
of the fully bound species of drug. Thus at any wavelength, 
assuming Beer's law to apply, the absorbance A is given by:-
A = e_ [DS]1 (4.1)a
Where e _ ' is the molar extinction coefficient of the bound 
B
drug, at a particular wavelength, [DS] is the concentration 
of drug bound to the protein, which in the presence of excess
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Fig. 4.2 - 4.5. Absorbance spectra for solution
containing 0 , 5.798 x 10~^,
2,899 X  10~^ and 1.449 x  10~^ 
mol dm  ^human serum albumin 
fraction V respectively.
In all cases the drug concentrations 
are / IC r ^  mol dm”
(1) 1.76, (2) 3.46, (3) 5.09,
(4) 6 .6 6 , (5) 8.18, (6 ) 9.64,
(7) 11.04, (8 ) 12.40.
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Fig 4.6 and 4.7
Interaction of M.T.T. with H.S.A. fraction V (experi­
mental method 1.17) drug concentrations are 6.130 x 10  ^
mol dm~~^  and 3.065 x 10~^ mol dm~^ respectively
Albumin concentrations/Imol dm~^
(1) O, (2) 2.841, (3) 5.580, (4) 8.203, (5) 10.72, (6 ) 13.17
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protein is equivalent to the total drug concentration, and 
1 is the pathlength.
Similarly, in the absence of protein, the absorbance 
is given by:-
A = [D]l (4.2)
Where is the molar extinction coefficient at a particular 
wavelength of the free dye and [D] is its concentration. 
Assuming the equilibrium to apply:
D + S = DS K = [PS] (4.3)
[d TTs ]
Where [S] is the concentration of free site, and K is the 
association constant for the reaction, at any intermediate 
concentration of protein the absorbance at any wavelength 
will be a composite of free and bound species and also the 
absorbance due to the protein.
In the sample beam the absorbance (A_ ) is given by
^Sa ” ^DF ^DB + ^n * ^FP ^BP '' ^SYS (4.4)
where A^^ = the absorbance due to free drug
A^g = the absorbance due to bound drug
A^ = the absorbance due to chromophores on the
albumin which do not participate in the 
reaction
App = the absorbance due to unbound binding sites 
on the albumin molecule
App = the absorbance due to bound binding sites 
on the albumin molecule
Agys = absorbance due to buffer, cells, etc.
The free site concentration is given by 
[S] = - [DS]
where [5 ^^^] = the total site concentration.
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Substituting corresponding extinction coefficients and con­
centrations
Aga ” Ep[D] + E'p[DS] + A^ + C p p  ([S^^^]-[DS]) +
:Bp[DS] + Agys (4.5)
Similarly in the reference beam
*ref = + ^f p ^^tot^ *sys (4.6)
thus the observed absorbance is given by
Y  =ep[D] + (c'a + E g p  -  Epp)[DS] (4.7)
let e'g +  E p p  -  E p p  =  E g  (4.8)
and since [D] = [D.^.] - [DS] where [D._.] is the totaltot tot
drug concentration
Y = Ep [Dtot^ + (Eg - Ep)[DS] (4.9)
When [D] is very small, i.e., in the presence of a large 
excess of albumin may be determined.
Thus values for [DS] may be calculated from any absorbance
(Table 4.1).
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From figs.4.6 and 4.7 
at 295nm
Eg = 3314 mol ^m^ 
Ep = 1935 mol ^m^
E - Er = 1379 mol 
®
-1
H.S.A. concentration = 5.798 X  10 ^ mol dm”^
(a )
Absorbance 
at 295nm
A/1
/m-1 /mol m
f^^tot^
/m-1
[DS] _3 
mol m -3/mol m
l/[DS_]j 3 
/mol m 3/mol m
.225 51.4 .0176 34.1 .0125 .0051 80.0 196
.435 99.4 .0346 67.0 .0235 .0111 42.6 90.1
.525 142 .0509 98.5 .0321 .0188 31.2 53.2
.818 187 .0666 129 .0421 .0245 23.8 40.8
.983 226 .0818 158 .0481 .0336 20.8 29.8
1.150 263 .0964 187 .0555 .0409 18.0 24.4
1.300 297 .1103 214 .0606 .0498 16.5 20.1
1.445 330 .1240 239 . .0656 .0584 15.2 17.1
H.S.A. concentration = 2.899 x lO”  ^mol dm”^
.218 49.8 .0176 34.1 .0114 .0062 87.7 161
.415 94.9 .0346 67.0 .0202 .0144 49.5 69.4
.590 135 .0509 98.5 .0263 .0246 38.0 40.6
.778 178 .0666 129 .0355 .0311 28.2 32.2,
.932 213 .0818 158 .0398 .0420 25.1 23.8
1.085 248 .0964 187 '.0447 .0517 22.4 19.3
1.241 284 .1104 214 .0509 .0595 19.6 16.8
1.390 318 .1240 239 .0565 .0675 17.7 14.8
H. —5 —3 S.A. concentration = 1.449 x 10 mol dm
.205 46.9 .0176 34.1 .0928 .0083 107 120.5
.415 94.9 .0346 67.0 .0202 .0144 49.5 69.4
.582 133 .0509 98.5 .0250 .0259 40.0 38.6
.752 172 .0666 129 .0311 .0355 32.2 28.2
.935 214 .0818 158 .0403 .0415 24.8 24.1
1.095 250 .0964 187 .0463 .0501 21.6 20.0
1.241 284 .1104 214 .0509 .0595 19.6 16.8
1.382 316 .1240 239 .0552 .0688 18.1 14.5
Table 4.1. Binding data for M.T.T.
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Calculating slopes and intercepts by linear regression, 
the values shown in Table 4.2 are obtained.
Table 4.2.
Albumin
concentration
 ^ moldm” ^
Intercept 
/mol'l m Gradient
n[P] 
/mol m”^ n
K
/lO ^ mol”àm^
1.449 1 0 0.35 0 . 1 0 6.9 2.9
2.899 15 0.44 0.067 2.31 3.4
5.798 8 0.81 0.13 2.27 9.9
In fact it is unlikely that the absorbance of albumin 
can be thought to change in a regular way, since binding 
may be accompanied by a conformational change. In order 
to overcome the problems encountered as a result of changes 
taking place in the albumin spectrum,compounds for further 
study were chosen, which absorbed at wavelengths greater 
than 300nm where the absorbance of albumin is small, and 
thus changes in the absorbance spectrum of albumin at wave­
lengths greater than 300nm would be negligable.
4.2 Sulindac - H.S.A. interactions
Sulindac^^ has an absorbance maximum at 322nm. The 
spectrum shows that, on addition of human serum albumin, 
there is a red shift, and the maximum absorbance diminishes 
(fig. 4.9 and 4.10).
One clear consequence of the equation
A = Ef [D] + E, [DS]
is that if the spectra of free and bound species overlap, 
i.e. at some point , and if the total drug concentra­
tion remains constant for a series of solutions, then all 
the spectra of the series will pass through that point.
(The isosbestic point)
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The Sulindac, human serum albumin system, shows a
clearly defined isosbestic point at 338nm. Data for this
system is shown in Tables 4.3 and 4.4.
Standard deviation for the free drug concentrations 
were calculated from the equation
S = (ICcr^]) _ (%[D^]2) (4.10)
(n-1 )
the coefficient of variation is given by
C = S X  100% (4.11)
[D]
[Ü] = the mean free drug concentration.
Ill
Figs. 4.9 and 4.10 Interaction of Sulindac with H.S.A.
fraction V (experimental method 1.18)
-4Drug concentrations are 1.998 x 10 
and 9.989 x 10~^ mol dm~~^  respectively
Albumin concentrations/lO  ^mol dm"*^  
(1) 0 , (2)2.841 (3) 5.580, (4) 8.203,
(5) 10.72, (6 ) 13.17, (7) 15.52,
(8 ) 17.80.
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Fig.4.11. Scatchard plot for Sulindac-H.S.A.
interactions.
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4.3 Mordant Oranqe-1 - H.S.A. interactions
The spectrum of the azo dye Mordant Orange 1, when com- 
plexed with human serum albumin (experimental method 1 .8 ), 
shows no isosbestic point (fig.4.12). This, together with 
matrix rank analysis (see ch.3), indicates that the simple 
single site model is not sufficient to explain the behaviour 
of this system. The next simplest model is one in which the 
drug may bind independent^ to two classes of sites on the 
albumin molecule in the following way:- 
Consider the two equilibria
K]
D + >  DS^ = [DS^] = _x  (4.12)
(B-x) x T sJTTD] (B-x )D^
D + $ 2  ^  DS 2  K 2  = [DS^] = y (4.13)
D, (C-y) y
Where x = the concentration of the first bound species
y = the concentration of the second bound 
species DS2
= the concentration of free drug
B = the total concentration of the primary site
C = the total concentration of the secondary 
site S2
= the total dye concentration
n^  ^ = the number of primary binding sites per
albumin molecule
n 2 = the number of secondary binding sites per
albumin molecule
P = the total albumin concentration
thus B = n^ P and C = n 2 P
also X = K^BD^ (4.14)
(k^D^+1 )
y — ^2 ^^f
( K ^ D ^  1) (4.15)
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Therefore since + x + y
Df = A - K^BD^ _ KgCDf
K^D^+l K2 D2 +I (4.16)
119
Fig. 4.12 Interaction of Mordant Orange 1 
with H.S.A,
Mordant Orange 1 concentration = 
1.558 X  lO"^ mol dm”^.
Albumin concentrations/10  ^ mol dm -3
(1) 0, (2) 
(5) 2.726, 
(8 ) 4.519, 
(11) 6.133, 
(14) 7.593,
.7214, (3) 1,415, (4) 2.083
(6 ) 3.344, (7) 3.942,
(9) 5.075, (10) 5.613,
(12) 6.636, (13) 7.122, 
(15) 8.049.
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The solution to this equation is:-
Kl ^2 + Kg - K, + B K, + C +
- ®tOt - Dtot %2 + %1 B + K; C),D^ - 
Dtot = ° (4.17)
At any wavelength, assuming that all three species obey 
■ Beer's law, the absorbance A is given by:-'
^  Df + X + Eg Y (4.1%)
Where ^  and are the respective molar extinction co­
efficients of the three species , DS^ and DSg.
If all seven constants are known (K^ ,^ , n^, TI2 ,
) the absorbance of any solution of the albumin-dye 
system, at a given wavelength,can be readily calculated.
In reality only is known. However, the other constants 
may be obtained by guessing values for them, substituting 
into 4,17 and 4.18, and comparing calculated absorbances with 
those measured experimentally. The guesses are then refined 
until calculated and measured absorbances match as closely 
as possible..
The cubic equation 4.17 is solved by Newton's method 
and has three real roots, only one of these, however, permits 
both X and y to be positive. The accuracy of the guesses 
is obtained from the relationship
S = (Aobs - *calc>"
Where A^^^ is the observed absorbance, and A^^^^ is the cal­
culated absorbance.
Results for the H.S.A. - Mordant Orange system are shown 
in Table 4.5.
It may be seen that although the results for the two
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experiments agree closely, good correlation between ob­
served and calculated absorbances may be obtained by 
using quite different values for the unknown constants.
This serves to illustrate the point that for fitting 
routines of this nature there are frequently a number of 
equally mathematically acceptable sets of parameters.
Matters may be improved by minimising S for absor­
bances of the solutions at five different wavelengths.
There is also an isosbestic point between the two bound 
species at 380nm which may be observed when the albumin 
concentration is high and hence the free dye concentration 
approaches zero. The method has the advantage that spectra 
for the three species may be plotted. Any data sets which 
produce sharp discontinuities in the spectra may be elimi­
nated .
In this instance absorbances were obtained at lOnm 
intervals for each spectrum. The five wavelengths chosen 
other than the isosbestic point wavelength were those at 
which the largest changes in absorbance were observed, in 
this case 350, 360, 370, 410 and 420 n m . The remaining
extinction coefficients at 380 and 390 nm were obtained by 
maintaining , K2 n^ and n 2 at the best values found and 
adjusting the four unknown extinction coefficients to their 
best values.
Table 4.6 and 4.7 show data for the best fits found 
at a dye concentration of 1.558 x 10  ^ mol dm Tables
4.8 and 4.9 summarise data obtained for the same system at 
different dye and albumin concentrations.
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Table 4.5 Typical absorbance and fitting data for
the Mordant Orange - H.S.A. system at 36Qim
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Table 4.6 Absorbance and fitting data for the Mordant
Qrange-l-H.S.A. system at multiple wavelengths
(Experimental method 1.8d)
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albumin 
conc^ 
/10~ mol dm”^
350 360 370 380 390 400 410 420
.7187 OBS
CALC
1.653
1.645
2.023
2.019
Absorbs
2.258
2.254
mce/dm
2.320
2.321
2.181
2.181
1.895
1.896
1.568
1.568
1250
1.241
1.410 OBS
CALC
1.442
1.442
1.819
1.821
2.103
2.103
2.242
2.246
2.199
2.197
1.991
1.987
1.705
1.699
1.367
1.376
2.075 OBS
CALC
1.335
1.335
1.714
1.716
2.021
2.024
2.201
2.210
2.213
2.218
2.048
2.056
1.785
1.794
1.474
1.476
2.715 OBS
CALC
1.269
1.272
1.653
1.653
1.975
1.977
2.187
2.190
2.238
2.238
2.112
2.111
1.870
1.869
1.559
1.555
2.332 OBS
CALC
1.227
1.231
1.609
1.612
1.945
1.946
2.178
2.179
2.256
2.256
2.155
2.155
1.927
1.929
1.621
1.619
3.928 OBS
CALC
1.198
1.201
1.582
1.583
1.922
1.924
2.171
2.172
2.272
2.272
2.192
2.192
1.977
1.977
1.673
1.672
4.501 OBS
CALC
1.184
1.180
1.568
1.561
1.915
1.908
2.174
2.167
2.293
2.285
2.231
2.221
2.023
2.017
1.719
1.715
5.055 OBS
CALC
1.163
1.163
1.543
1.544
1.897
1.895
2.165
2.163
2.297
2.296
2.247
2.246
2.050
2.049
1.749
1.750
5.591 OBS
CALC
1.150
1.150
1.531
1.531
1.888
1.886
2.162
2.160
2.306
2.305
2.267
2.266
2.075
2.076
1.778
1.779
6.109 OBS
CALC
1.138
1.139
1.518
1.520
1.877
1.878
2.158
2.158
2.311
2.313
2.281
2.283
2.096
2.099
1.799
1.803
6.609 OBS
CALC
1.134
1.131
1.513
1.511
1.872
1.871
2.158
2.157
2.322
2.320
2.297
2.297
2.119
2.118
1.824
1.824
7.094 OBS
CALC
1.127
1.124
1.506
1.504
1.865
1.866
2.155
2.156
2.325
2.325
2.306
2.310
2.128
2.134
1.833
1.841
7.564 OBS
CALC
1.115
1.118
1.495
1.498
1.858
1.862
2.153
2.155
2.325
2.330
2.315
2.320
2.146
2.147
1.856
1.856
8.014 OBS
CALC
1.113
1.113
1.493
1.493
1.858
1.858
2.158
2.154
2.334
2.334
2.331
2.329
2.165
2.159
1.877
1.869
wa velength/nm
350 360 370 380 390 400 410 420
/ 1-1 2 e,/mol m
— 1 2 E_/mol” m
/ 1-1 2E^/mol m
630.8
798.3
1302
870.5
1049
1534
1129
1256
1630
1376
1376
1585
1599
1352
1397
1696
1213
1136
1650
1018
886.4
1488
796.8
677.5
Ki = 
=
C o
2.54 X 10 mol” dm 
1.02 X 1 0  ^mol ^ dm^
n, = 2.14
n2 = 16.9
Dye conc^ - 1.558 x 10 ^
mol dm”^
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Table 4.7 Absorbance and fitting data for the Mordant 
Qrange-l-H.S.A. System at multiple 
wavelengths
(Experimental method 1.8c)
wavelength/nm 128
Albumin 
concent] 
/lo” mol
ration
dm"
350 360 370 380 390 400 410 420
.7214 OBS
CALC
1.625
1.620
1.993
2.003
2.233
2.234
2.299
2.302
2.169
2.170
1.888
1.885
1.573
1.569
1.250
1.245
1.415 OBS
CALC
1.415
1.414
1.817
1.806
2.078
2.082
2.222
2.226
2.183
2.186
1.984
1.977
1.703
1.704
1.390
1.385
2.083 OBS
CALC
1.312
1.312
1.721
1.703
2.021
2.005
2.192
2.192
2.208
2.208
2.027
2.048
1.799
1.801
1.486
1.487
2.726 OBS
CALC
1.250
1.253
1.634
1.643
1.957
1.960
2.171
2.174
2.229
2.228
2.107
2.104
1.877
1.875
1.563
1.565
3.344 OBS
CALC
1.209
1.216
1.589
1.602
1.922
1.931
2.160
2.164
2.245
2.246
2.151
2.148
1.931
1.933
1.623
1.626
3.942 OBS
CALC
1.186
1.190
1.566
1.574
1.909
1.911
2.158
2.157
2.263
2.260
2.187
2.183
1.977
1.978
1.669
1.674
4.519 OBS
CALC
1.173
1.171
1.550
1.553
1.895
1.896
2.155
2.153
2.277
2.272
2.213
2.212
2.011
2.014
1.707
1.712
5.075 OBS
CALC
1.163
1.157
1.536
1.536
1.888
1.885
2.153
2.150
2.286
2.282
2.242
2.234
2.048
2.043
1.749
1.743
5.613 OBS
CALC
1.147
1.146
1.525
1.524
1.877
1.876
2.151
2.148
2.295
2.290
2.258
2.253
2.071
2.067
1.771
1.768
6.133 OBS
CALC
1.141
1.138
1.518
1.513
1.872
1.869
2.149
2.146
2.299
2.297
2.272
2.268
2.089
2.086
1.792
1.789
6.636 OBS
CALC
1.131
1.131
1.506
1.505
1.861
1.863
2.144
2.145
2.297
2.303
2.274
2.281
2.094
2.103
1.797
1.806
7.122 OBS
CALC
1.122
1.125
1.497
1.498
1.856
1.859
2.142
2.144
2.302
2.308
2.286
2.292
2.112
2.116
1.817
1.820
7.593 OBS
CALC
1.120
1.120
1.495
1.492
1.856
1.855
2.144
2.143
2.313
2.312
2.299
2.301
2.130
2.128
1.838
1.833
8.049 OBS
CALC
1.118
1.116
1.493
1.487
1.854
1.851
2.142
2.142
2.313
2.315
2.309
2.309
2.139
2.138
1.849
1.844
wavelength/nm
350 360 370 380 390 400 410 420
e,/mol"^m^
— 1 2 Ep/mol" m
— 1 2
E^/mol m
634.9
795.7
1298
846.5
1074
1531
1118
1261
1626
1369
1369
1578
1591
1340
1391
1705
1180
1131
1649
1001
883.5
1479
786.6
672.5
= 2.16 X 10^ mol”^ dm^ 
^2 = 1.15 X 10^ mol”^ dm^ 
n^ = 2.37
ng = 16.9
Dye conc^ = 1.558 x 10“  ^
mol dm“^
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Dye concentration/10“"^ mol dm"^
0.7792 1.558 2.453 Mean
10  ^X /mol  ^dm^ 2.20 2.35 3.01 2.52
lO”  ^X K2 /mol"^ dm^ 1.47 1.07 0.98 1.17
"l 2.82 2.26 1.76 2.28
*^ 2
11.4 16.9 15.6 14.6
Table 4.9 Binding constants and proportionality
constants obtained for the
Mordant Orange 1 - H.S.A. system
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- 15.0
(N
CN
- 10.0
•H
•H
360 370 390380 4P0 410
Wavelength/nm
Fig.4.13 Resolved extinction coefficient for the three 
dye species present in the Mordant Orange 1 
- H.S.A. system.
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CHAPTER 5 
THE
SPECTROPHOTOMETRIC MEASUREMENT 
OF THE
INTERACTIONS BETWEEN SOME ORGANIC ANIONS
AND
HUMAN SERUM ALBUMIN
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5.1. Mordant Yellow - H.S.A. interactions
The method described in Chapter 4 to obtain binding 
parameters for Mordant Orange 1, was applied to the Mordant 
Yellow 12/human serum albumin system (Experimental method 
1.9). A typical series of spectra is shown in fig.5.1.
The overall change in the dye spectrum on binding with 
albumin is not as pronounced as that with Mordant Orange 1. 
Nevertheless a matrix rank analysis of the spectra indicates 
the existence of three species (p87) in solution, of which 
one is the free dye. Since there is a virtual isosbestic 
point at 387nm which hardly moves throughout the course of 
the titration it is not possible to use this point in the 
same way as for Mordant Orange 1, because absorbance changes 
at this point are so small. Therefore, five wavelengths were 
used for the 'best fit' determination, 350, 360, 370, 440 
and 450 nm. It was found that the most consistent values for 
the binding parameters were obtained by 'pooling' the results 
from three separate titrations. Several different permuta­
tions of the sets of data were tried, and found to give essen­
tially the same binding parameters (Table 5.6).
Table 5,1 - 5.3 give absorbance and fitting data for 
the Mordant Yellow 12 - H.S.A. system, as a result of pooling 
data from 3 titrations. The binding parameters obtained are 
given in Table 5.4.
Extinction coefficient values at the remaining wave­
lengths were obtained by fixing , K2 , and n 2 at the 
best values previously found and adjusting the unknown extinc­
tion coefficients to their best values.
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Fig. 5.1. Interaction of Mordant Yellow 12 with
H.S.A. (Experimental Method 1.9e)
Mordant Yellow 12 concentration = 
5.405 X 10”  ^ mol dm”^
Albumin concentrations Were as 
follows/10"5 mol dm"3 
(1) 0 , (2) 0.7197, (3) 1.412,
(4) 2.078, (5) 2.719, (6 ) 3.337, 
(7) 3.932, (8 ) 4.507, (9) 5.062, 
(10) 5.599, (11) 6.117, (12)
6.619, (13) 7.104, (14) 7.574,
(15) 8.029.
135
i
a
i m liiii-T!— r-rM-:'rtfiTÜ!!!
iiiJjU! nil
: ^ :|i I : !
340 360 380 400 420
Wavelength/nm
440
136
Wavelength/nm
Albumin
concentration
/10~^ mol dm”^
350 360
Absorb
370
ance/cm
440 450
.7788 OBS
CALC
1.198
1.193
1.536
1.536
1.794
1.797
1.211
1.203
1.013
1.004
1.528 OBS
CALC
1.118
1.112
1.454
1.450
1.733
1.732
1.243
1.229
1.056
1.041
2.248 OBS
CALC
1.063
1.062
1.394
1.396
1.685
1.690
1.266
1.260
1.083
1.077
2.942 OBS
CALC
1.038
1.029
1.360
1.359
1.659
1.660
1.289
1.286
1.111
1.107
3.611 OBS
CALC
1.006
1.006
1.330
1.334
1.630
1.639
1.305
1.307
1.131
1.130
4.256 OBS
CALC
.994
.989
1.314
1.315
1.618
1.623
1.321
1.324
1.150
1.147
4.878 OBS
CALC
.978
.976
1.301
1.300
1.607
1.611
1.335
1.337
1.161
1.161
5.478 OBS
CALC
..960
.966
1.280
1.289
1.591
1.602
1.344
1.347
1.173
1.172
6.059 OBS
CALC
.983
.958
1.303
1.280
1.589
1.594
1.353
1.355
1.182
1.180
6.620 OBS
CALC
.951
.952
1.275
1.273
1.582
1.588
1.376
1.362
1.202
1.188
7.162 OBS
CALC
.946
.947
1.262
1.267
1.573
1.584
1.371
1.367
1.195
1.193
7.687 OBS
CALC
.928
.942
1.243
1.263
1.559
1.579
1.374
1.372
1.200
1.198
8.196 CBS
CALC
.951
.939
1.271
1.259
1.577
1.576
1.385
1.375
1.209
1.202
8.688 CBS
CALC
.935
.936
1.257
1.255
1.570
1.573
1.385
1.379
1.214
1.206
Table 5.1. Absorbance and fitting data for the 
Mordant Yellow 12/H.S.A. system
Experimental method 1.9a. . Dye concentration 
= 2.397 X 10 mol dm
w avelength/nm 137
Albumin 
concentration 
/10“ mol dm~
350 360
absorb;
370
nce/cm
440 450
.7597 OBS
CALC
1.819
1.835
2.334
2.352
2.713
.2.728
1.790
1.787
1.486
1.482
1.490 OBS
CALC
1.721
1.731
2.226
2.242
2.635
2.648
1.815
1.802
1.525
1.513
2.193 OBS
CALC
1.655
1.658
2.169
2.164
2.576
2.589
1.838
i.829
1.559
1.550
2.870 OBS
CALC
1.595
1.607
2.103
2.109
2.535
2.545
1.870
1.860
1.595
1.586
3.522 OBS
CALC
1.554
1.569
2.053
2.067
2.501
2.512
1.899
1.889
1.630
1.619
4.151 OBS
CALC
1.527
1.540
2.027
2.035
2.475
2.486
1.920
1.914
1.650
1.647
4.758 OBS
CALC
1.513
1.517
2.009
2.009
2.469
2.464
1.943
1.936
1.675
1.670
5.344
CALC
1.490
1.498
1.982
1.989
2.441
2.447
1.943
1.936
1.689
1.690
5.910 OBS
CALC
1.479
1.483
1.968
1.971
2.434
2.433
1.954
1.955
1.705
1.707
6.458 OBS
CALC
1.481
1.470
1.961
1.957
2.427
2.421
1.970
1.970
1.723
1.721
6.987 CBS
CALC
1.458
1.460
1.952
1.945
2.418
2.411
1.989
1.984
1.730
1.733
7.499 OBS
CALC
1.458
1.450
1.945
1.935
2.418
2:402
1.998
1.995
1.746
1.743
7.995 OBS
CALC
1.449
1.443
1.931
1.926
2.402
2.395
2.011
2.005
1.744
1.752
8.476 OBS
CALC
1.447
1.436
1.934
1.918
2.411
2.388
2.009
2.013
1.762
1.760
Table 5.2 Absorbance and fitting data for the Mordant 
Yellow 12/H.S.A. System.
Experimental method 1.9c. Dye concentration 
= 3.586 X 10"^ mol dm-3
138
Wavelength/nm
Albumin 
concentration 
/lO”  ^mol dm”^
350 360
Absorb
370
ance/cm
440
1
450
.7197 OBS
CALC
2.855
2.831
3.616
3.613
4.153
4.161
2.672
2.687
2.201
2.217
1.412 OBS
CALC
2.699
2.713
3.483
3.489
4.071
4.073
2.686
2.690
2.233
2.240
• 2.078 OBS
CALC
2.635
2.614
3.390
3.385
3.998
3.997
2.706
2.702
2.270
2.268
2.719 OBS
CALC
2.553
2.536
3.303
3.303
3.936
3.936
2.718
2.723
2.293
2.300
3.337 OBS
CALC
2.478
2.478
3.280
3.240
3.902
3.888
2.759
2.750
2.341
2.334
3.932 OBS
CALC
2.446
2.432
3.207
3.191
3.861
3.849
2.779
2.779
2.370
2.367
4.507 OBS
CALC
2.386
2.396
3.141
3.151
3.824
3.816
2.807
2.806
2.395
2.398
5.062 OBS
CALC
2.363
2.365
3.131
3.117
3.790
3.789
2.821
2.833
2.432
2.427
5.599 OBS
CALC
2.318
2.339
3.065
3.088
3.753
3.765
2.850
2.857
2.446
2.453
6.117 OBS
CALC
2.331
2.316
3.063
3.062
3.749
3.744
2.873
2.878
2.473
2.476
6.619 OBS
CALC
2.279
2.297
3.026
3.041
3.719
3.726
2.894
2.898
2.491
2.497
7.104 OBS
CALC
2.313
2.279
3.035
3.021
3.710
3.710
2.905
2.915
2.507
2.516
7.574 OBS
CALC
2.249
2.264
2.987
3.004
3.701
3.695
2.923
2.931
2.521
2.533
8.029 OBS
CALC
2.231
2.251
2.978
2.989
3.689
3.683
2.923
2.946
2.533
2.548
Table 5.3 Absorbance and fitting data for the Mordant 
Yellow 12/H.S.A. system.
Experimental method 1.9e. Dye con-
concentration = 5.405 x 10“  ^mol dm
wavelength/nm
350 360 370 440 450
—1 2 E, /mol” m
/ 1-1 2 E./mol m
/ 1-1 2 E^/mol m
319.4 
488.8
548.5
443.4
635.4.
694.1
587.7
752.6
788.0
659.8
452.1
497.5
591.1
375.6
406.4
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Kl = 
«2 =
"l “
n^ =
1.28 X 1 0  ^mol'l dm^ 
1.27 X  10^ m o l ” ^  d m ^  
4.18 
18.3
Table 5.4. Binding parameters and extinction
coefficients used for the absorbance 
fitting data in tables 5.1 - 5.3.
Titration Dye concentration 
/1 0”^mol dm”
Albumin conc^ 
/lO”  ^mol dm”
lA 2.397 .7788 - 8.688
2A 3.586 .7597 - 8.476
3A 5.405 .7197 - 8.029
IB 2.394 .7957 - 8.877
2B 3.566. .7573 - 8.449
3B 5.382 .7317 - 8.163
Table 5.5. Concentration ranges for the
six Mordant Yellow 12/H.S.A. 
titrations.
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Data sets 
used
"l ^2 -1 3/lO mol dm /lO^ mol”^ dm^
lA, 2k, 3A 4.18 18.3 1.28 1.27
IB, 2B, 3B 4.44 17.2 1.92 1.78
IB, 2k , 3k 4.26 15.7 1.43 1.52
I k , 2B, 3B 4.33 20.5 1.72 1.30
lA, 2B, 3A 4.19 16.4 1.30 1.26
IB, 2A, 3B 4.42 19.4 1.82 1.52
lA, 2A, 3B 4.24 21.7 1.64 1.30
IB, 2B, 3A 4.26 15.0 1.43 1.49
Table 5.6. Binding parameters obtained with 
various permutations of the 
Mordant Yellow 12 - H.S.A. 
absorbance data sets.
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380 420400 440
wavelength/nm
Fig 5.2 Resolved extinction coefficients for the 
three dye species present in the Mordant 
Yellow 12 - H.S.A. system (experimental 
methods 1.9a, 1.9c, 1.9e).
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As a means of comparing these results with others 
obtained in this work, and with other workers, it is use­
ful to plot data in the most widely accepted form; either 
as a Scatchard plot (Fig.5.3) or as a Klotz plot (Fig.5.4) 
as described in Chapter 1 (p 45). It is also useful to plot 
the theoretical free drug concentration against total dye 
concentration for a constant albumin concentration (in this 
case 1 . 0 0 0  x 1 0  mol dm ^ ), which gives an easily visualised 
concept of the extent to which the dye is bound by the 
protein (Fig.5.5) and also gives a direct comparison with 
ultrafiltration methods (see Chapter 6 ). A computer pro­
gramme was, therefore, written which calculated and drew 
theoretical Scatchard, Klotz and binding extent plots when 
given the binding parameters K^, K2 , n^ and n 2 for the dye*
In this instance two sets of parameters and their mean para­
meters were used, these are given in Table 5.7.
Data set
" 1 " 2
%1
/lO^ mol”^ dm^
%2
/lO^ mol”^ dm^
A 4.18 18.3 1.28 1.27 1
B 4.44 17.2 1.92 1.78
M (Mean) 4.31 17.7 1.60 1.53
Albumin Concentration = 1.000 x 10  ^ mol dm ^
Mordant Yellow 12 concentration = 5.000 x 10 
to 5.000 X 10-4 niol dm“^
-5
Table 5.7 Parameters used for Klotz, Scatchard
and extent of binding plots.
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In this instance the total bound drug concentration/
= [DS^] + [DSg]
The quantity r is defined as [DS^J+Ed S^]
Tp ]
where [P] = the protein concentration.
The interaction of a number of other dyes have also 
been investigated with H.S.A. in an exactly analagous way 
to that described for Mordant Yellow 12. Mean values for 
the four binding parameters , K2 , n^  ^ and n 2 are presented 
in Table 5.17, together with other experimental information 
The resolved spectra for the three species of each dye are 
shown in Fig.5 .6 to 5.12.
The theoretical Scatchard and Klotz plots for all the 
dyes are shown in Fig. 5.13 and 5.14. The theoretical 
binding extent plot is shown in Fig.8,1.
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5.2 Resolved spectra for various dye- H.S.A. interactions
Tables 5.8 - 5.16 Resolved spectra data for various dyes 
with H.S.A.
Table 5.8 Mordant Yellow 12
wavelength
/nm
(mean)
/loo mol~^ m^
^2 (mean) 
/loo mol”^ m^ /loo mol m
350 3.28 4.89 5.48
360 4.55 6.34 6.94
3 70 5.98 7.52 7.88
380 7.12 8 . 0 0 8.15
390 7.77 7.83 7.73
400 7.60 6.95 6.93
410 7.10 6.09 6.39
420 6.90 5.59 6.06
430 6.92 5.13 5.64
440 6.56 4.52 4.97
450 5.87 . 3.74 4.06
Table 5.9 Mordant Yellow 7
wavelength
/nm
(mean) 
/lOOOmol"^ m^
(mean)
— 1 2 
/lOOomol" m 1 2 /lOOOmol" m
330 0.535 0.798 0.948
340 0.704 0.994 1.17
350 0.945 1 . 2 2 1.39
360 1 . 2 1 1.33 1.48
3 70 1.38 1.27 1.39
380 1.41 1.08 1.16
390 1.26 0.817 0.852
400 0.932 0 . 6 0 6 0.598
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- 15.0
• H
•Hy-i
-5.0
• H4->
• H
340 35P 360 370 380 390
wavelength/nm
Fig. 5.6 Resolved extinction coefficients for the three 
dye species present in the Mordant Yellow 7 - 
H.S.A. system.
Table 5.10 Alizarin Yellow GG
149
wavelength
/nm
E2 Imean) 
/lOOO mol'l m^
E 2 Imeanj 
/lOOO mol'l m^
Sf 1 ,
AOOO mol'^ m
320 0.946 1.33 1.46
330 1 . 2 2 1.65 1.81
340 1.54 1.96 2.13
350 1.91 2 . 2 1 2.35
360 2.17 2 . 2 0 2.27
3 70 2.16 1.93 1.92
380 1.95 1.47 1.43
390 1.49 1 . 0 0 0.930
Table 5.11 4-azobenzenesulphonic acid
wavelength
/nm
(mean) 
/lOOO mol'^m^
E 2 (mean) 
/lOOO mol“^ m^ 1 2 /lOOO mol m
300 1.32 1.23 1.69
310 1.82 1.63 2 . 1 1
320 2 . 1 1 1.97 2.33
330 2 . 2 0 1.97 2 . 2 0
340 1.98 1.71 1.77
350 1.48 1.17 1.15
Table 5.12 5-Phenylazosalicylic acid
wavelength
/nm
(mean ) 
/lOOO mol“^ m^
£2 (mean) 
/lOOO mol'l m^ 1 2 /lOOO mol~^ m
320 0 . 8 6 6 1.38 1.48
330 1.25 1.61 1.78
340 1 . 6 8 1.82 2 . 0 2
350 2.33 1.91 2.09
360 2.70 1.71 1.83
3 70 2.72 1.33 1.39
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-  20.0
COo
•H
•H
•H
•H
380370340 350330
wavelength/nm
Fig.5. 7v Resolved extinction coefficients for the three
dye species present in the Alizarin Yellow GG -
H.S.A. system.
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•H
•H
' 10.0
340320 330310
wavelength/nm
Fig. 5.8 Resolved extinction coefficients for the
three dye species present in the
4-azobenzeneysili^honicacid - H.S.A. system.
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•H
'la•H
•H
360340330
wavelength/nm
Fig. 5.9 Resolved extinction coefficients 
for the three dye species present 
in the 5-phenylazosalicylic acid - 
H.S.A. system.
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Table 5.13 4-hydroxyazobenzene-4'-sulphonic acid
wavelength
/nm
(mean) 
/lOOO mol“  ^ m^
^2 (mean) 
/lOOO mol'l m^ i 2/lOOO mol m
320 1.15 0.825 1.25
330 1.59 1.14 1.69
340 2 . 0 1 1.48 2.06
350 2.29 1.75 2.28
360 2.30 1 . 8 8 2.24
3 70 2.19 1.71 1.98
380 1.89 1.46 1.60
Table 5.14 Mordant Yellow 10
wavelength
/nm
(mean) 
/lOOO mol“^ m^
^ 2 (mean) 
/lOOO mol'l m^
' f . ,
/lOOO mol m
330 .991 1.19 1.45
340 1.26 1.47 1.74
350 1.57 1.71 1.94
360 1.83 1.67 1.89
3 70 1.84 1.50 1.61
380 1.63 1.24 1 . 2 1
390 1.25 0.853 0.801
Table 5.15 Mordant Orange 1
wavelength
/nm
(mean) 
/lOOO mol'l m^
02 (mean) 
/lOOO mol'l
1 2 
/lOOO mol” m
350 0.684 0.745 1.30
360 0.909 1 . 0 1 1.53
3 70 1.15 1 . 2 2 1.62
380 1.37 1.37 1.58
390 1.56 1.36 1.39
400 1.63 1 . 2 2 1.13
410 1.57 1.03 0.878
420 1.39 0.820 0 . 6  70
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20.0
•H
•H
•H
•H
4->
- 10.
360350340330
wavelength/nm
Fig.5110 Resolved extinction coefficients for the 
three dye species present in the 
4-hydroxyazobenzene-4'-sulphonic acid - 
H.S.A. system.
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10.0
•H
•HU-1
•H
360350 380370
wavelength/nm
Fig. 5.11 Resolved extinction coefficients for the
three dye species present in the Mordant
Yellow 10 - H.S.A. system.
Table 5.16 Bromophenol Blue
156
wavelength
/nm
(mean) 
/lOOO mol“  ^ m^
^2 (mean) 
/lOOO mol”^ m^
e
f 1 9 
/lOOO mol m”
5 70 3.66 4.06 5.44
580 4.54 4.47 6.98
590 6.04 4.87 8.26
600 7.87 4.98 7.30
610 7.84 4.57 4.24
620 5.09 3.69 1.83
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- 80.0
- 70.0
- 60/0
-50.0CNJ
40•H
•H ■ 30.0
•H
- 20.0
• 10.0
6106Cp59058p
wavelength/nm
Fig. 5.12 Resolved extinction coefficients 
for the three dye species present 
in the Bromophenol Blue - H.S.A. 
system.
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5.3 Binding Data for dye - H.S.A. interaction;
Compound
Mean
/lO^mol"^
dm^
Mean
/lO^mol”^
dm"^
" 1 * 2
Experimental 
method 
(see Ch. 2)
Mordant 
Yellow 12 1.60 1.53 4.31 17.7 1.9
Mordant 
Yellow 7 2 . 0 0 1.06 3.41 6.87 1 . 1 1
Alizarin 
Yellow GG 3.71 2.18 5.46 10.9 1 . 1 0
4-azobenzene
sulphonic
acid 3.65 0.929 1.14 4.61 1.13
5-phenylazo­
salicylic
acid 3.81 4.08 1.31 9.39 1 . 1 2
4-hydroxy- 
azobenzene-4'- 
sulphonic 
acid
2.33 1.65 2.17 4.18 1.15
Mordant 
Yellow 10 7.82 3.90 2.93 2 . 6 8 1.14
Mordant 
Orange 1 2.52 1.15
2.28 14.62 1 . 8
Bromophenol
Blue 11.5 3.67
1.78 3.46 1.16
Table 5.17 Summary of binding parameters for H.S.A.
dye interactions.
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4-azobenzene sulphonic acid
4-hydroxyazobenzene sulphonic 
Mordant Yellow 10 ;
Mordant Yellow 7
Mordant Orange 1.
5-phenylazosalicylic acid 
Mordant Yellow 12 
Alizarin Yellow GG
20.0
acid
hlS.O
m
h 10.0
4.03.0
Fig. 5.13 Theoretical Scatchard plots for,the azo dyes with 
H.S.A. (U.V/visible data fitting method).
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4-azobenzene sulphonic acid
4-hydroxyazobenzene sulphonic acid 
Mordant Yellow 10
Mordant Yellow 7 
Mordant Orange 1
5-phenylazosalicylic acid 
Mordant Yellow 12 
Alizarin Yellow GG
■80.0
■60.0
m
■40.0
m
0.400.30
1 /r
Fig. 5.14 Theoretical Klotz plots for the azo dyes with 
H.S.A. (U.V./visible data fitting method)
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CHAPTER 6 
THE
APPLICATION OF ULTRAFILTRATION 
TO THE STUDY OF 
THE
INTERACTIONS OF HUMAN SERUM ALBUMIN
WITH
AZOBENZENE DERIVATIVES.
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The principal advantage of ultrafiltration over the 
spectroscopic techniques is that values for free ligand 
concentrations are determined experimentally rather than 
via an intermediate data fitting step. Practically, however, 
the technique suffers from rather more inherent errors.
6.1. The changing volume system
It may be shown that in the ideal system, equilibrium
data can be obtained directly by measurement of the effluent
ligand concentration in the following way
Consider the cell initially to contain a volume of 
solution V. Assuming firstly a single, independent site 
system the following equilibrium applies
D + ^ DS^ K = [DS^]
[d T T ^ ]
Initially the following equations apply
[D] = Mp [S] = Mg [DS] = M^g
~  ~  " V
Where M ^ , Mg and M^g are the masses of free ligand, free
site and ligand site complex within the cell.
Therefore K = Mj^g/Mg.CD] = M^g
~ T 7  Mprô]
Let the volume of solution in the cell decrease by an amount 
6V. Therefore
^ ^DS ^ ^DS
(V-6 V)/(V-6 V) Mg[D]
In the ideal case free ligand diffuses perfectly through 
the filter, whilst the protein and ligand-protein _ complex 
are completely rejected. The concentration of free ligand 
[D], therefore remains unaltered throughout the course of
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the experiment.
By similar reasoning it may be shown that in the case 
of a two independent site system the following equations 
apply:-
"^1 " ”dS1 ^^2 “ ”dS2
M^TTd ] M%FD]
where the subscripts 1 and 2 refers to the two classes of 
site.
In the case of cooperativity between sites (see dis­
cussion p2 l6 )the technique may still be applied.
K.
D -f P DP K, = DP or K, = [D]
1 T pTTd ] 1
K2
DP + D # DgP Kg = DgP Kg = MpgP.[D]
[DPT[D]
D^P + D D(n+l)-P ^ + 1  = D(n+l)P K^+l = "p(n+l)
[dTpTTdT [m_ p][d ]n Dn
where [P] = free protein concentration
[D^P] = Concentration of the ith ligand-protein
complex
[D] = The free ligand concentration
Mp = The mass of free protein in the cell
Mp.P = The mass of the ith ligand-protein complex
in the cell.
This theory is not applicable, however, if:
1) An increase in protein concentration lead to an 
alteration in the number of sites or their equilibrium con­
stants . This may arise as a result of protein polymerisa­
tion or conformational change.
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---- 1-------------- 1--------------1------------- J------- F----- 1--------- rr
Effluent dye concentration/10”  ^ mol dm--:
Rejection of Evans Blue by UMIO 
ultrafilter (experimental method 5)
Fig. 6.1
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2) At higher concentrations a larger proportion of 
protein or dye is bound to the membrane or cell walls.
3) The free dye is significantly rejected by, or some 
of the protein passes through, the ultrafilter.
6.2. Membrane and cell wall binding
In order to counter this effect the apparatus is 
initially equilibrated with the solution. Since the extent 
of dye or protein binding may depend on their concentration 
an equivalent volume to that in the test solution is run off
6.3. Membrane rejection
This is a commonly occuring phenomenon and depends on 
both the ligand and type of ultrafilter used.
Evans Blue is seriously rejected by Amicon UMIO
filters. Fig. 6.1, curve (a), shows the effect of running
Evans Blue through a UMIO filter (experimental method 5)
and measuring internal and external dye concentrations.
Rejection is even more pronounced if the cell is firstly
equilibrated with a dye-albumin solution. Curve (a) is the
regression 'best straight line', whilst curve (b) is fitted
to a polynomial of the type :-
2
m
y = a + bx + Cx
2inimising the function ^(y-ye)^^
o
Where ye is the experimental interior cell dye concentration, 
and y is the calculated value. Rejection to this extent 
makes interpretation of binding data very difficult.
None of the phenylazobenzoic or phenylazosalicylie 
acid derivatives used in this study were seriously rejected 
by Amicon YMIO filters.
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The rejection problems encountered with the UMIO 
filter may have been partially due to using a buffer 
solution of concentration 0.0666 mol dm”  ^ in phosphate, 
which exceeds the manufacturer's recommendation of 
0.05 mol dm“  ^ maximum. A UM2 filter was also tried, but 
filtration was unacceptably slow.
Both YMIO and UMIO filters have a nominal cut-off
molecular weight of 10000. The UM2 filter has a nominal
cut off of 1 0 0 0 .
The effects of rejection may be minimised by allowing 
only a small volume of the test solution to pass through 
the filter (^Icm^) before measuring the concentration.
6.4. Ultrafiltration data fitting
Assuming the two independent classes of site system 
described in Chapter 4 (pi 17) , the concentration of free dye 
may be calculated from given equilibrium constants and 
binding site numbers by the equation
+ (K, + Kg - D K. Kg + BK^Kg + CK^^KgjD^
+ K g O D ^  - = 0  (6 .1 )
where B = n^P and C = n 2 ?
Best values for K^, K2 , n^ and n 2 for ultrafiltration data
obtained with the azo dyes and human serum albumin des­
cribed in experimental method 6 , were calculated in the
following way :-
Theoretical values of were initially calculated 
for a series of solutions from guessed values of , K2 ,
n^ and n2 • These were compared with the measured values.
The binding parameters were then adjusted by means of a 
'simplex' routine so as to minimise the function
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([D.exp]. - [D.calc].)^ 
o ^ 1' 1
where [D^exp]^ = The experimentally measured concentration 
of the ith dye solution.
[D^calc]^ = The calculated concentration of the ith 
dye solution.
The roots of the cubic equation were determined directly, 
rather than by using Newton's method, using the following 
method :-
3 2If a x + bx + cx + d = 0
the equation may be transformed to
y^ + 3py + 2q = 0 (6 .2 )
2
where 2 q = 2 b _ be + d 
TtI^ - 3T2 ¥
2
3p = 3ac - b 
3a^
and y = X 4- b/3a.
2 3It can be shown that where D = q + p
If D>0 then the equation 6.2 has 1 solution (one real
and two imaginary roots)
If D<0 then the equation has 3 solution (three different 
roots).
If D = O then the equation has one solution for p =
q = 0 (three coincident zero roots) and 2 solutions for
3 2p = -g ^ 0 (two of three real roots coincide).
In the case of P^O the real root may be found using 
Cardan's formula
y = u + V
where u =
V =
In the case of D <  0 the three real roots are obtained 
from the formulae :-
y 2 = -2 r cos i  0
y 2 = + 2 r cos ^  cos"^(-1 ) - 0 ^
y 2 = + 2r cos ^  cos~^(-1 ) + 0  ^
where 0 = cos ^ and where all trigonometric functions
r
are in radian measure.
As before, in the real situation there a ne usually 
three real roots to the equation 6 .1 , of which only one 
allows X and y to be positive. Although a single root may 
be found if the simplex adjusts any parameter to an unreal 
value.
6.5. Results
Table 6.1 gives data for the ultrafiltration t>f 
Mordant Yellow 7 with human serum albumin (experimental 
method 6 ) at the best parameter fit. Tables 6.2 to 6 . 8  
give experimental ultrafiltration data for seven other azo 
dyes with human serum albumin. Figures 6.2 to 6.9 show 
the result of the ultrafiltration of the eight dyes. In 
each case curve (a) is the 'best f it' curve, using the 
best values found for , K2 , n^ and n 2 « Curve (b) is the 
theoretical ultrafiltration curve from the binding parameters 
obtained by the U.V/visible data fitting method in chapter 5.
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5.000 3.289 . 4.317 4.239 4.129
5.000 3.289 4.317 4.239 4.157
5.000 3.289 4.317 4.239 4.131
4.500 3.284 4.241 3.747 3. 692
4.500 3.284 4.241 3.747 3.711
4.500 3.284 4.241 3.747 3.728
4.000 3.277 4.147 3.258 3.263
4.000 3.277 4.147 3.258 3.189
4.000 3.277 4.147 3.258 3.262
3.500 3.268 4.026 2.771 2.857
3.500 3.268 4.026 2.771 2.809
3.500 3.268 4.026 2.771 2 . 613
3.000 3.255 3.867 2.288 2.265
3.000 3.255 3.867 2.288 2.319
3.000 3.255 3.867 2.288 2.248
2.500 3.236 3. 649 1.811 1.880
2.500 3.236 3. 649 1.811 1.856
2.500 3.236 3. 649 1.811 1.851
2.000 3.205 3.337 1.346 1.414
2.000 3.205 3.337 1.346 1.406
2.000 3.205 3.337 1.346 1.383
1.500 3.146 2.864 0.8989 0.8970
1.500 3.146 2.864 0.8989 0.9280
1.000 3.146 2.864 0.8989 0.9430
1.000 3.007 2.108 0.4885 0.5160
1.000 3.007 2.108 0.4885 0.4310
1.000 3.07 2.108 0.4885 0.4940
0.500 2.493 0.9448 0.1562 0.1280
0.500 2.493 0.9448 0.1562 0.1330
0.500 2.493 0.9448 0.1562 0.1080
= 1.91 X 10^ mol”^dm 
= 4.52
= 1.49
4 -1 
X 10 mol dm = 3.28,
Table 6.1. Ultrafiltration fitted data for Mordant Yellow 7
with human serum albumin (1.000 x 10  ^mol dm
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-4.0
-2.0
•H
" 1.0
3.0 4.02.0
Total dye concentration/lO mol dm
Fig. 6.2 Ultrafiltration curve for Mordant Yellow 7 with 
H.S.A. (1.000 X lO”  ^mol dm” )^
Binding parameters for fitted line (a)
= 1.91 X 10^ mol'l dm^ = 1.49 x 10^ mol"^ dm^
n^ = 3.28 n.2 = 4.52
Binding parameters for line (b) (from Ch. 5 pl58)
= 2.00 X 10^ mol~^ dm^ = 1.06 x lo"^  mol“^ dm^
n^ = 3.41 ri2 = 6.87
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Total dye 
concentration 
/lO” mol dm ^
Experimental free 
dye concentration 
/lO mol dm”^
Experimental free 
dye concentration 
/lO mol dm”
Experimental free 
dye concentration 
/lO” mol dm”^
5.000 4.288 4.200 4.226
4.500 3.821 3.979 3.825
4.000 3.375 3.344 3.330
3.500 2.837 2.967 2.856
3.000 2.356 2.440 2.3 63
2.500 1.976 1.886 1.969
2.000 1.499 1.545 1.489
1.500 1.068 1.089 1.059
1.000 0 . 632 0.633 0 . 645
0.500 0.244 0.218 0.232
Table 6.2. Ultrafiltration data for Mordant Yellow 10 with 
human serum albumin (1.000 x 10*"^ mol dm
Total dye 
concentration 
/lO” mol dra”^
Experimental free 
dye concentration 
/lO” mol dm”^
Experimental free 
dye concentration 
/lO” mol dm”^
Experimental free 
dye concentration 
/lO” mol dm”^
5.000 2.962 3.012 2 . 9 6 1
4.500 2.722 2.545 2 . 6 66
4.000 2.2 9 6 2.176 2.289
3.500 1.932 1.884 1.915
3.000 1.473 1.392 1.489
2.500 1.063 1.127 1.034
2.000 0.771 0.760 0.727
1.500 0.441 014 63 0.415
1.000 0.2 2 6 0.243 0.210
0.500 0.097 0.080 0.078
Table 6.3. Ultrafiltration data for Mordant Orange 1 with
human serum albumin (1.000 x 10  ^mol dm
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■4.0
m
■3.0
-2.0
-1.0
M
Total dye concentration/10~ mol dm
Fig. 6.3 Ultrafiltration curve for Mordant Yellow 10 
with H.S.A.
Binding parameters for fitted line (a) . _ _
= 6.76 X 10^ mol'l dm^ ^2 = ^.08 x 10 mol dm
n^ = 3.25 n^ = 3.29
Binding parameters for line (b) ' (from Ch.5 p 158)
= 7.82 X 10^ mol"^ dm^
n^  ^= 2,93
Kg = 3.90 X 10^ mol ^ dm^
TI2 — 2.68
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■ 4.0
- 3.0m
- 2.0
- 1.0
4.02.01.0
Tbtal dye concentration/lo”  ^mol dm”^
Fig. 6.4 Ultrafiltration curve for Mordant Orange 1 with 
H.S.A. (1.000 X  10“  ^mol dm“ )^
Binding parameters for fitted line (a)
= 1.14 X  10~^ m o l ~ ^  d m ^  
n^ = 3.08
Kg = 2.31 X  lo"^ m o l ” ^  ^  
ng = 16.67
Binding parameters for line (b) (from Ch. 5 pi5,8 )
= 2.52 X 10^ mol ^ dm^
n^ = 2.28
Kg = 1.15 X 10^ mol ^ dm^
ng = 14.62
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Total dye 
concentration 
/lO mol dm”^
Experimental free 
dye concentration 
/10 mol dm”^
Experimental free 
dye concentration 
/lO mol dra"^
Experimental free 
dye concentration 
/lO mol dm”^
5.000 3.352 3.168 3.265
4.500 2.899 3.148 2.969
4.000 2.793 2.707 2.771
3.500 2.249 2.352 2.242
3.000 1.860 1.944 1.896
2.500 1.285 1.441 1.344
2.000 1.162 1.039 1.109
1.500 0.724 0.765 0.709
1.000 0.486 0.433 0.4 67
0.500 0.229 0.198 0.212
Table 6. 4 Ultrafiltration data for Mordant Yellow 12 with 
human serum albumin (1.000 x lO”^ mol dm” )^
Total dye 
concentration 
/lO mol dm*^
Experimental free 
dye concentration 
f l o T  mol dm”^
Experimental free 
dye concentration 
/lO” mol dm ^
Experimental free 
dye concentration 
/ l O "  mol dm”^
5.000 3.867 3.887 3.710
4.500 3.412 3.480 3.321
4.000 2.834 2.967 2.862
3.500 2.426 2.542 2.420
3.000 2.085 1.978 2.064
2.500 1. 648 1.5 6 6 1. 614
2.000 1.190 1.169 1.162
1.500 0.780 0.749 0.716
1.000 0.400 0.382 0.372
0.500 0.126 0.130 0.130
Table 6. 5 Ultrafiltration data for 5-phenylazosallcyllc acid
with human serum albumin (1.000 x 10  ^mol dm
175
‘4.0
m
- 2.0
•H
■ 1.0
2.0 3.0 4.0
-3Total dye concentration/10 mol dm'
Ultrafiltration curve for Mordant Yellow 12 with 
H.S.A. (1.000 X 10”  ^mol dm“ )
Fig. 6.5
Binding parameters for fitted line (a)
= 3.78 X 10^ mol”^ dm^ 
n^  ^= 4.47
K2 = 1.04 X 10^ mol“^ dm^ 
n2 = 13.39
Binding parameters for fitted line (b) (from Ch.5 pl58)
= 1.60 X 10^ mol”^ dm^
n^ = 4.31
K2  = 1.53 X 10^ mol ^  dm^
n2 = 17,70
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m
- 2 . 0
- 1.0
3.02.01.0 4.0
-3Total dye concentration/I0 mol dm
Fig. 6.6 Ultrafiltration curve for 5-phenylazosalicylic 
acid with H.S.A. (1.000 x 10-5 dm"^)
Binding parameters for fitted line (a)
= 4.57 X 10^ mol' dm^ Kg = 3.24 x lo"^  mol"^ dm^
"1 = 1.75
ng = 11.66
Binding parameters for line (b) (from Ch.5 p i 58)
K = 3.81 X 10^ mol' dm^ Kg = 4.08 x 10  ^mol”^ dm^
1.31 ng = 9.39
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Total dye 
concentration 
/10”^mol dm”’^
Experimental free 
dye concentration 
/lO mol dm”^
Experimental free 
dye concentration 
/lO mol dm”
Experimental free 
dye concentration 
/lO” mol dm”^
5.000 4.382 4.174 4.382
4.500 3.903 4.080 3.984
4.000 3.522 3.479 3.483
3.500 2.921 3.017 2.970
3.000 2.537 2.64 6 2.559
2.500 2.175 2.0 68 2.054
2.000 1 . 662 1 . 645 1. 669
1.500 1.222 1.225 1.202
1.000 0.702 0.724 0.726
0.500 0.352 0.338 0.335
Table 6.6 Ultrafiltration data For 4-hydroxyazobenzene-4'- 
sulphonic acid with human serum albumin
(1.000 X 10“  ^mol dm"3)
Total dye 
concentration 
/10“ mol dra”^
Experimental free 
dye concentration 
/lO” mol dm”
Experimental free 
dye concentration 
/lO” mol dm”^
Experimental free 
dye concentration 
/lO mol dm”^
5.000 4.076 4.040 4.217
4.500 3. 669 3.404 3.474
4.000 3.102 2.842 2.925
3.500 2.393 2.32 6 2.5 2 6
3.000 2.205 2.270 2.255
2.500 1.837 1.839 1.852
2.000 1.425 1.396 1.451
1.500 1.030 1.007 0.9 62
1.000 0.578 0.581 0.572
0.500 0.215 0.191 0.190
Table 6.7 Ultrafiltration data for azobenzene-4-sulphonic
acid with human serum albumin (1.000 x 10  ^mol dm
178
ro
2.0
1.0
2.01.0 3.0 4.0
—4 '—3Total dye concentration/10 mol dm”
Fig. 6.7 Ultrafiltration curve for 4-hydroxyazobenzene- 
4'-sulphonic acid with H.S.A. (1.000 x 
10”  ^mol dm-3)
Binding parameters for fitted line (a)
= 2.96 X 10^ mol”l dm^ 
n^ = 2.37
= 7.58 X 10^ mol ^ dm^ 
TI2 -  4.43
Binding parameters for line (b) (from Ch.5 p 158 )
= 2.33 X 10^ mol”^ dm^
n^  ^= 2.17
K2  = 1.65 X 10^ mol ^ dm^
ng = 4.18
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ro
-3.0
- 2.0
.1.0
4.03.02.01.0
Ibtal dye concentration/10  ^mol dm~^
Fig. 6.8 Ultrafiltration curve for 4-azobenzene- 
sulphonic acid.
Binding parameters for fitted line (a)
= 4.79 X 10^ mol~^ dm^ 
n^ = 1.73
Kg = 2.37 X  l o ' ^  m o l ' l  d m ^  
ng = 6.48
Binding parameters for line (b) (from Ch.5 pl58)
= 3.65 X  10^ mol  ^dm^ Kg = 9.29 x 10^ mol  ^ImP
n^ = 1.14 ng = 4.61
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Total dye 
concentration 
/lO mol dm
Experimental free 
dye concentration 
/lO mol dm”^
Experimental free 
dye concentration 
/lO mol dm”^
Experimental free 
dye concentration 
/lO” mol dm”^
5.000 3.358 3.512 3. 600
4.500 3.172 3.278 3.245
4.000 2.780 2.802 2.799
3.500 2.356 2.348 2.329
3.000 1.920 1.908 1.834
2.500 1.315 1.376 1.456
2.000 1.144 1.098 1.077
1.500 0.7 52 0. 684 0. 690
1.000 0.399 0.381 0.381
0.500 0.169 0.127 0.118
Table 6.8 Ultrafiltration data for Alizarin Yellow GG with 
human serum albumin (1.000 x 10 ^ mol dm
181
4.0
m
-3.0
•H
4-1
- 2.0
- 1.0
3.02.01.0
Total dye concentration/10~^ mol dm”^
Ultrafiltration curve for Alizarin Yellow GG 
with H.S.A. (1.000 x 10 mol dm” )
Fig. 6.9
Binding parameters for fitted line (a)
= 5.98 X 10^ mol”  ^dm^ 
n^  ^s= 4.18
Kg = 7.66 X 10^ mol”l dm^ 
ng = 14.89
Binding parameters for fitted line (b) (from Ch.5 pi58)
= 3.71 X 10^ mol”l dm^
n^ = 5.46
Kg = 2.18 X 10^ mol ^
ng = 10.9
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CHAPTER 7
SPECTROPHOTOMETRIC STUDIES 
OF
COMPETITION REACTIONS BETWEEN SOME 
AZOBENZENE DERIVATIVES AND BROMOPHENOL BLUE,
WITH
HUMAN SERUM ALBUMIN.
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7.1. The two independent site model for competitive 
reactions
The shapes of a series of absorption spectra, produced 
as a result of the titration of a solution of Bromophenol 
Blue with human serum albumin, can be altered by the intro­
duction of another dye. This effect occurs even though the 
second dye has no absorption of its own over the wavelength 
range measured. The effect is not due to a direct interaction 
between the two dyes. For all the compounds described in 
this Chapter, over the wavelength range measured, the spec­
trum of Bromophenol Blue (with no albumin present) is un­
affected by the introduction of the second dye.
The effect is clearly shown in Fig. 7.1 - 7.3, which 
show the absorption spectra for the titration of Bromophenol 
Blue with human serum albumin in the presence of successive­
ly larger Mordant Yellow 10 concentrations.
As described in Chapter 4, the spectrum of Bromophenol 
Blue changes as H.S.A. is added, but, in general, the 
changes in shape, are smaller if a second dye is present. 
Furthermore the change in shape is even smaller when the 
dye concentration is increased.
This seems to indicate that less Bromophenol Blue is 
bound by the albumin when the other dye is present, and 
shows competition between the two dyes for the albumin 
molecule.
If the two site model for the interaction of Bromophenol 
Blue with human serum albumin is assumed, as proposed in 
Chapter 4, then the concentration of the free dye, and the 
two bound species in any solution can be calculated from
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Fig 7.1. Interaction of Bromophenol Blue with
H.S.A. (experimental method 1.16c)
Bromophenol Blue concentration = 
4.417 X 10~^ mol dm” .
Albumin concentrations/lo”^ mol dm”  ^
were as follows :-
(1) O, (2) .3872, (3) .7595, (4)
I.118, (5) 1.463, (6 ) 1.795, (7)
2.116, (8 ) 2.425, (9) 2.724, (10)
3.012. (11) 3.291.
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Fig. 7.2 Interaction of Bromophenol Blue
(4.442 X  10~^ mol dm~^) with H.S.A. 
(experimental method 2 .1 b), in the 
presence of Mordant Yellow 10 
(4.425 X  10~^ mol dm”^)
Albumin concentrâtions/lo"^ mol dm” ^
were as follows :-
(1) 0, (20 0.3552, (3) 0.6968,
(4) 1.025, (5) 1.342, (6 ) 1.647,
(7) 1.941, (8 ) 2.225, (9) 2.499,
(10) 2.763.
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Fig. 7.3 Interaction of Bromophenol Blue (4.429 
X 10~^ mol dm"^) with H.S.A. (experi- 
mental method 2 .If) in the presence of 
Mordant Yellow 10 (1.770 x 10*~^ mol dm  ^)
— 5 — 3Albumin concentrations/IO" mol dm~
were as follows :-
(1) 0, (2) 0.3586, (3) 0.7034, (4)
1.035, (5) 1.355, (6 ) 1.663, (7)
1.960, (8 ) 2.246, (9) 2.523, (10)
2.790, (11) 3.048.
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the extinction coefficients calculated in Chapter 5, by 
the following method :-
If [B^], [BS^] and [BS2 ] are the concentrations of free 
Bromophenol Blue and the two albumin bound species respec­
tively, the absorbance (A^) of the solution at a wavelength 
X^, per unit pathlength is given by:-
*1 ° [BSg] (7.1)
where and are the molar extinction coefficients
for the three species B^, BS^ and BS2 at the wavelength . 
Similarly for the same solution at two further wavelengths 
%2 and X^. The competiting dye does not absorb at X^, X^ 
or X3 .
A 2 = C 2f + £21 [BS^] + £22 [BS2 ] (7.2)
^3 == ^3f ^®f^ + ^31 [BS^] + E32 [BS2 ] (7.3)
Therefore, by re-arranging 7.1, 7.2 and 7.3 to eliminate 
[BS2 ] from the equations, the following may be written :-
^22 ( ^ 11 ^®^i^ '*■ ^if “ ^1  ^ ^1 2 ^ ^ 2 1  ^®^i^
®2f [Bj] - Ag) (7.4)
^32 ( ^ 11 [B^] - A^) = [BS^^] +
®3f [Bf] - A3 ) (7.5)
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Substituting the equalities
* = ‘^If ^ 2 2 - ^2 f ^1 2 ' A' =  632 -  E 33 e ^2
® = ' :ll ^ 2 2 - ^ 2 1 ^2 2 > ®' = < ^ H  ^32 " ^31 ^1 2 >
^ " "^2 *^12 - *1 ®2 2 > = (A3 E^ 2 - 6 3 3 )
7.4 and 7.5 become on re-arrangement
A [Bg] + B [BS^] 4- C = 0 (7.6)
A ' [B^] + B [BS^] + C  = 0 (7.7)
equating for [B^] and [BS^]
[B ] = B C  - B'C (7.8)
B'A - BA'
(BS ] = CA' - C'A (7.9)
AB' - A'B
(BS^] = - £lf(BC' - B'C) + (CA ' - C'A) - A^(B'A-BA')
E,^ (B'A - BA')
(7.10)
The simplest competitive model for a two site system 
is one in which there are n^ mutual primary sites and n 2 
mutual secondary sites on the albumin molecule. Thus for 
Bromophenol Blue
Kni
Bf + S^ # BS^ = [BS^] (7.11)
Kb2 [Bprs^]
®2 " ®®2 Kgg = BSg (7.12)
[bJTTSj ]
and for the competing dye 
K
D + S^ h DS^ = [DS^] (7.;3)
TdTTs^]
K
D t S 2  r DSj ^2 ^ ^^^2^ (7.14)
T dT T ^ ]
Therefore from 7.11 and 7.12 
[S^] = [BS^]
r ÊpT î Ç i  
[S^] = [BS^]
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tBf].Kb2
If the total primary binding site is given by
^ 1 tot ^  CDSj^] + [BS^] +
then DSj^  = — [BS^] — [S^]
Similarly DS^ = ^ 2 t o t ^  [BS^] - [S^]
If the total competing dye concentration is then
[D] = - [DS^] - [DS^]
Hence and can be calculated from 7.13 and 7.14.
Competition experiments between Bromophenol Blue and 
eight azo dyes were performed as described in Ch.2 (experi­
mental method 2). Absorbances for the solutions at the five 
wavelengths at which the largest changes in absorbance 
occurred were used in the calculation of the concentrations 
of the three Bromophenol Blue species present, using the 
calculated e values for the three Bromophenol Blue species 
(see p 156).
Equations 7.8, 7.9 and 7.10 require only three absorbances 
for each solution. A Fortran computer program was written 
which obtained values for the concentrations of the three 
Bromophenol Blue species for every permutation of the five 
absorbance values. Thus ten values for the concentration of 
the three Bromophenol Blue species were calculated for each 
solution.
Tables 7.1 - 7.8 give examples of one titration for each 
of the eight azo compounds. Table 7.9 summarises the equi­
librium constant values obtained for each compound.
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In calculating the values for and there are a 
small number of data sets which give negative values for 
the constants. These drastically affect the mean and 
K2 values. Therefore, as well as the mean values of and 
K2 , a mean value has also been calculated in which any data 
set which gives a negative value for or K2 is disregarded 
The number of data sets giving positive values is given.
It may be more meaningful to plot the free Bromophenol 
Blue concentration against albumin concentration in the 
presence of a competitor. Fig. 7.4 and 7.5 show the data 
plotted in this way.
7.2. Results
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Table 7.9 Binding data for the competition of azo
dyes and Bromophenol Blue with H.S.A.
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'S BN fH •H iH fH 0 <
8.525
8.525 
17.05
4.437
4.390
4.398
-1.09
1.42
2.29
-7.37
-4.42
2.96
9.84
6.59
2.31
3.28
3.42
5.50
100
100
100
62
62
73
17.05 4.432 2.45 0.140 2.55 2.19 100 74
4.435 4.448 2.212 0.669 5.75 3.44 100 42
4.435 4.445 1.92 0.449 4.74 2.11 100 44
X fH
S 0
8.871
8.871
4.468
4.468
-0.419
1.30
-4.73
-1.07
2.53
2.93
1.67
2.40
100
100
62
66
17.74 4.476 1.20 0.645 1.27 1.14 100 91
17.74 4.465 1.14 -0.0845 1.19 2.02 100 90
4.426 4.459 0.805 -0.278 2.31 1.22 100 69
4.426 4.465 -0.643 -0.642 1.53 0.737 100 66
<N 8.852 4.428 0.532 -0.118 0.990 1.38 100 92
g B 
ES
Z ^
8.852
17.70
17.70
4.437
4.448
4.432
0.745
0.460
0.432
0.153
0.282
0.502
1.09
0.469
0.438
0.721
0.289
0.550
100
90
90
91
88
88
Table 7.9 (continued)
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Fig. 7.4 and 7.5. Binding plots for Bromophenol
Blue at approximately constant 
concentration (4.430 x 10~^ 
mol dm^ ) in the presence of 
competitor dyes
The competitor dye concentrations were as 
follows : X
1 . 5-Phenylazosalicylic acid. 1.767 X 10-4 mol dm” ^
2 . Mordant Yellow 7, 1.773 X 10-4 mol dm”^
3. Mordant Yellow 10, 1.770 X 10-4 mol dm”^
4. 4-azobenzenesulphonic acid 2 . 0 0 2 X 10-4 mol dm”^
5. 4-hydroxyazobeneze-4 
sulphonic acid. 1.767 X 10-4 mol dm”^
6 . Alizarin Yellow GG, 1.705 X 10-4 mol dm”^
7. Mordant Orange 1, 1.774 X 10-4 mol dm”^
8. Mordant Yellow 12, 1.770 X 10-4 mol dm-3
205
Competitor
dye
1.
2.
3.:
4.
s..
Phenylazosalicylic acid 
Mordant Yellow 7 
Mordant Yellow 10 
4-azobenzene sulphonic acid 
4-hydroxyazoben zene-4 
sulphonic acid 
Theoretical Branophenol
Blue binding curve in 
the absence of a com­
petitor dye
—5 —3
Albumin concentration/10 mol dm
Fig. 7.4. Ihe effect of Competitor dyes on the binding 
of Bromophenol Blue to H.S.A.
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Alizarin Yellow GG 
Mordant Orange 1 
Mordant Yellow 12
Theoretical Bromophenol 
Blue binding curve in 
the absence of a com­
petitor dye
Competitor
dye
ro
-3.0
in
•H
•p
■ 1.0
2.01.0 3.0
-3
Albumin concentration/10 mol dm
Fig. 7.5 The effect of Competitor dyes on the binding 
of Bromophenol Blue to H.S.A.
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CHAPTER 8
DISCUSSION.
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8 . 1. Preliminary Spectrophotometric experiments
Spectrophotometry appeared to be a very suitable 
technique for studying ligand-protein interactions, pro­
vided that changes occur in the spectrum of either the 
ligand or the protein. Some preliminary experiments were, 
therefore, conducted, which eventually led up to the 
technique described in Chapter 4, for studying the inter­
actions of M.T.T. with H.S.A. - fraction V.
Initially the protein used was plasma, separated by 
centrifugation from whole human blood. Various drug-plasma 
solutions were studied, the absorbance of the drug being 
measured at a single wavelength. Inconsistent results led 
to the substitution of H.S.A. fraction V for the plasma.
In the most recent experiments this has been substituted 
with crystallised lyophilised H.S.A. It was also found that 
spectral changes at wavelengths, shorter than 300 nm were 
inconsistent. This is thought to be due to complex confor­
mational effects taking place in the protein when it binds 
to ligands. Some early experiments were conducted, so that 
difference spectra were measured, using a tandem cell tech-' 
nique. This technique was performed in the following way:-
B,
Tandem quartz cells
Sample beam Reference Beam
After performing the usual baseline correction for the two 
cells a drug-protein solution was placed in both Ag and Bg 
compartments of the 'tandem' cells. A^ was filled with a
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protein solution of twice the concentration of the protein 
in the sample compartments Ag and Bg and B^ was filled with 
a drug solution of twice the concentration of the drug in 
Ag and Bg. A difference spectrum over a wavelength range 
was then recorded. A titration was then performed in a 
similar way to that described in method 1 .
The method has no inherent advantage over techniques 
measuring the whole U.V/visible spectrum of each of the 
drug-protein solutions. In fact, there must be a greater 
uncertainly in the reproducibility of the experiment since 
for any series of experiments, four titrations must be 
simultaneously performed rather than two in the conven­
tional method. Furthermore, visualisation of the spectral 
changes involved is more difficult from difference spectra 
than from whole spectra. For this reason the technique 
was abandoned in favour of measurement of the whole absorp­
tion band.
Some first and second derivative spectra of the drug- 
protein solutions were also measured. The spectra should 
show more clearly than normal spectra the existence of 
new bands emerging as shoulders on the absorption bands 
of the free drug spectrum. However, for quantitative work 
amplitudes of first and second derivitive spectra at a 
particular wavelength must be measured from the chart paper 
rather than from a digital read out. This leads to larger 
inaccuracies, than in the normal mode, and so derivitive 
spectrophotometry was not used further.
2 1 0
8 .2 . M .T .T .- H .S .A . interactions
M.T.T. shows a very clear change in spectrum on addi­
tion of H.S.A. fraction V. A new band appearing with Xmax 
at 295nm. Of all the compounds studied this is the only 
example in which a new side band appears, rather than a 
smooth progression of the spectrum towards a different 
shape. Since the treatment of the experimental data given 
in Chapter 4 failed to give consistent values for the equi­
librium constants and number of binding sites, the data 
should possibly be treated as a two binding site case. In 
this case the band at 295nm is that of the primary bound 
species, and the secondary bound species has a spectrum 
similar in position and shape to that of the free drug.
Even so, it is doubtful whether spectral changes at these 
wavelengths can be treated meaningfully when albumin spec­
tral changes are largely contributing to the spectral 
alteration. In this case the absorption bands of the pro­
tein and of the ligand overlap.
8.3. Sulindac - H.S.A. interactions
U.V/visible spectra of Sulindac show a well defined 
isosbestic point when a solution of a constant concentra­
tion of the drug is titrated with H.S.A. This probably 
indicates the presence of one class of binding sites. The 
data may be treated to give the number of a single class of 
binding sites per protein molecule and an equilibrium con­
stant. Even so, the fact that this treatment is success­
ful does not exclude the possibility of there being more 
than one class of binding sites. In the two independent 
sites model, the spectrum of the secondary complex may be 
almost identical with that of the free drug. Although
Matrix rank analysis shows the existence of two drug 
species, this does not exclude the possibility of there 
being more species, since there may be two or more spec- ' 
trophotometrically indistinguishable species present.
8.4. Matrix rank analysis
Upon the addition of H.S.A. the spectra of the majority 
of compounds studied changed in ways not consistent with 
there being a single class of binding site on the albumin 
molecule. Matrix rank analysis was introduced as a means 
of estimating the numbers of species in solution.
The technique should not be subject to many experi­
mental errors due to the fact that the accuracy of the 
method depends only on the purity of the compounds used and 
the accuracy to which absorbances can be measured.
8.4.1. Warfarin
Matrix rank analysis of Warfarin-H.S .A . interactions 
seems to show the definite existence of a single class of 
binding sites and the possible existence of a second.
The literature contains many references to Warfarin-
94H.S.A. interactions. Much of the more recent literature, 
g c 1 79  171
' ' * suggests that Warfarin binds to several dif­
ferent sets of sites, although there is a strong implica­
tion^^ that this may be via a cooperative rather than
an independent site mechanism (see section 8.5.4.).
8.4.2. Sulindac
■ As already pointed out, Sulindac spectra indicate that 
there are only two spectrophotometrically distinguishable 
species in solution. However, even at very high Sulindac 
concentrations competition studies between Sulindac
2 11
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and Bromophenol Blue still indicate three Bromophenol Blue 
species in solution.
If Sulindac has only one class of binding sites, 
which is also one of the classes of Bromophenol Blue bind­
ing sites, then at high concentration of Sulindac, this 
class of sites should be effectively unavailable to Bromo­
phenol Blue. The Bromophenol Blue-H.S.A. system should, 
under such conditions, appear to be a one class of binding 
sites system. Since it appears that under such conditions 
binding of Bromophenol Blue to both classes of site is 
impared, there may also be more than one class of Sulindac 
binding site.
8.4.3. Methyl Orange
Matrix rank analysis of the spectra of Methyl Orange-
H.S.A. spectra, in common with most of the following azo- 
benzene derivatives shows the probable existence of two 
types of binding site. Analysis of the spectra at high 
albumin concentrations, at which the free dye concentration 
is likely to be very low, show the existence of only two 
species, which is consistent with this model. It is highly 
significant that the spectral changes on addition of bovine 
serum albumin differs from those with H.S.A., and suggests 
that the primary B.S.A. site is rather different from that 
in H.S.A.
8.4.4. Azobenzene derivatives
The spectra of 5-phenylazosalicylic acid, 4-azobenzene 
sulphonic acid, and 4 -hydroxyazobenzene-4 '-sulphonic acid, 
only indicate the existence of two distinguishable species. 
There may only be one bound species, although it seems 
more likely that two or more species have rather similar
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spectra as shown in Chap. 5. Matrix rank analysis of 
the other azo dyes are consistent with there being two 
binding sites on the albumin molecule.
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8.5. The spectrophotometric data fitting technique
It is important to realise that there are a number 
of equally valid models which may be applicable to a set 
of data. The following section describes some of the 
options available.
8.5.1. Non-specific binding
An option which is usually ignored in discussions of 
this nature is that in which the ligand does not bind to 
any specific site. Alternatively, there may be a large 
number of sites, but they are each only available when the 
albumin molecule is in a particular conformation. Since 
the albumin molecule exists partly as an aHelix and partly 
as a random coil, the very large number of conformations 
available would make binding of this nature effectively 
non-specific.
8.5.2. Specific independent site binding
Single class of binding sites:-
125—12 7A frequently used model " for obtaining binding con­
stants and binding site numbers is that of the protein 
having a single class of binding sites. From this study 
it would appear that single class independent site systems 
are rare; the only case here in which this model could be 
applied being that of Sulindac with H.S.A. Although matrix 
rank analysis of the spectra of 5 -phenylazosalicylic acid,
4-azobenzenesulphonic acid and 4-hydroxyazobenzene-4'-sulphonic 
acid with H.S.A. can only differentiate two species in 
solution which may indicate single class site binding.
Since many studies in which the single class site model 
is used interpet data via the Scatchard plot (see p 4 5) 
it should be observed that Scatchard plots for a two inde-
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pendent class site system can give apparently linear plots, 
e.g. the theoretical plots given in Fig. 5.13 (pl59) for 
all the dyes except for Mordant Yellow 10, Mordant Yellow 7 
and 4-hydroxyazobenzene-4'-sulphonic acid could easily be 
interpreted as straight lines, especially if they were 
plotted through data showing the degree of scatter common 
to multi-phase methods for the measurement of drug-blood 
protein binding.
8.5.3. Specific multipule independent site binding
In these cases there are two or more classes of inde­
pendent sites. If there are j classes of site, then the 
equilibrium constant for each class of site is given by
K. = [S.D]
[S“ 3t d ] (8.1)
for the reaction Sj + D ^ S^D
where [Sj] is the concentration of the unoccupied jth 
class of sites,[D] is the concentration of the ligand and 
[SjD] is the concentration of the ligand-site complex.
The mole ratio of bound ligand per mole of total 
protein (r) is given by:-
r = = ^ K^[P] (8 .2 )
1 + K [D]
where n is the number- of classes of binding sites on each 
protein molecule. In some instances it is more convenient 
to consider the system from the macromolecular point of 
v i e w . I n  this case the sequential addition of ligand 
to the protein (P) is considered. The equilibrim constants 
for the sequential binding are
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P + D # PDi Kf = [PDj]
[P][P]
PD3 + D # PDg
4  = [PDg]
[PD^JED]
PD(i-l) + D # PD. 4  = [PD^]
[PD(i_i)][D]
in which case
r = k 8[ d ] + K® [D]2 .....
1 + K^Cd ] + K® k| [D]2 ....
and K- = K. + K- + ... K- = K .,
k| = Ki Kj + Ki K3 +  + K-1 + Kg K3 + K.
K4 + ....  + %2 %2
= f  ' I  ''32
J ^-1
c Ç c n—i+ 1 n—i+2
r8 k| .....  r8 = I.i L
2 -^1 +!
K ^2
8.5.4. Cooperative site binding.
Several a u t h o r s , h a v e  suggested that ligand 
macromolecular interactions may take place cooperatively. 
Parsons and Vallner^^^ have given a thorough treatment of 
cooperativity.
Cooperative binding of a ligand refers to the situa­
tion where occupation of a binding site on a macromolecule 
by a ligand affects in some way the subsequent binding of 
the ligand to other sites on the macromolecule. The co- 
operativity is positive when subsequent binding of the ligand 
by the macromolecule is facilitated, and negative when it 
is impaired.
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Positive and negative cooperativity are often thought 
to arise as a result of a conformational change in the 
macromolecule when bound to the ligand. This mechanism 
is referred to as allosterism.
Cooperativity may arise as a result of very small 
displacements of the peptide chains, or perhaps merely from 
strains in the structure of the macromolecule.
Both positive and negative cooperativity may also be 
caused by electrostatic interactions between bound ligand 
molecules.
Positive cooperativity may result from the creation 
of new binding sites on the macromolecule when the ligand 
binds to a pre-existing site. Conversely, negative coopera­
tivity may arise from the destruction of some pre-existing 
sites caused by the binding of ligand to another site. The 
sites could be destroyed as a result of steric interference 
between bound ligand molecules or as a result of a confor­
mational change in the macromolecule, or again by electro­
static effects.
Cooperative binding involving conformational changes 
is likely to introduce a large entropy term to the equation 
for the free energy of the reaction, and there must, there­
fore, be a correspondingly large, negative, enthalpy term.
In their three related papers. Parsons and Vallner 
consider the cases of one site creators of binding sites, 
two site creators of sites, and destruction of pre-existing 
binding sites, and positive and negative site site coopera­
tivity. In every case they show how Scatchard plots can 
be created with convex, concave, or linear shapes depending
218
on the relative magnitudes of the equilibrium constants at 
the various sites.
8.5.5. Choice of model used
Throughout this work all data, with the exception of 
Sulindac-H.S .A . interactions, have been interpreted assuming 
a two independent site model. The n and K values obtained 
give concave theoretical Scatchard plots. These plots, 
however, could also be consistent with a model using three 
or more independent sites, or with a cooperative model.
The single largest error factor in the titration of the 
azo-dyes with albumin was in the accuracy of the micro­
pipette with which albumin could be added to the cell, intro­
ducing an error factor of - 0 .5 %.
The average error between the measured and calculated 
values of J absorbance values for a parameter fit is given 
by
N 2 /
f = 100 X 2_ (A-measured - A ..calculated ) / N
T- k j  measured
If f is greater than 1% any change in the binding parameters 
n ^ , TÏ2 and the extinction coefficients and Eg 
which produce a decrease in the value of f,.represents a 
real improvement in the parameter fit. If f falls below 
1 % any change in the parameters producing a decrease in f 
does not represent a meaningful improvement, i.e. all para­
meter sets producing f values of less than 1 % are equally 
applicable to the system.
The values quoted for the binding parameters in this 
work are the best values, i.e. s (and hence f) having the 
minimum values. In no case did f exceed 1% and in many cases
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did not exceed 0.5%. This means that no meaningful im^ ? 
provement could be made to improve the fit of measured 
to calculated data because the fit is better than the re­
producibility of the experimental data. It also means 
that there are a number of parameter sets which are equally
as good as those quoted.
Although using a three site model would introduce a 
further three parameters into the equations to be fitted, 
which would undoubtedly enable a mathematical improvement 
in the 'goodness of fit', this would not represent a real 
physical improvement.
It is also not really justifiable to apply a three
site model when in most cases matrix rank analysis of the
spectra indicate only three spectrophotometrically distin­
guishable species (one being the unbound species).
Equally a cooperative model could probably be used to 
produce as good a fit as the independent site model, but 
it could not be decided solely from the spectrophotometric 
experiments described in Chap. 5, or the ultrafiltration 
experiments which is the better model.
It would appear that the model used gives good agree­
ment between projected dye binding curves from the best fit 
parameters obtained from the spectrophotometric method 
described in Chap. 5 (fig.8.1), and those obtained experi­
mentally by ultrafiltration (fig.8.2). It is apparent that 
different sets of binding parameters can yield almost iden­
tical binding curves. For example, in fig. 6.4. curves a 
and b are almost identical, yet the values of , Kg, n^ 
and ng are significantly different. It appears, therefore.
that the most significant thing is not the individual 
numbers, but the values that they give when combined to­
gether in an equation such as (4.17).
KiKzDf] + (K3+K2 - K3K2 + BK3K2 + C K^K2>Dj2 +
- ®tot - D^ot %2 + B + K2 C)Df - = 0
(4.17)
The binding curves produced by equation (4.17) for the 
eight azo-dyes are summarised in Figs. 8.1 and compared 
with corresponding ultrafiltration curves in Fig.8 .2, the 
binding parameters used being in Table 8.1.
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Comparison of binding constants obtained from the spectrophoto— 
metric and ultrafiltration techniques.
221
sf«ctrophotometric Ultrafiltration
Compound rH1 in E  O  <T3
^2
•—1 
1
o
"l "2
I
in^ E  O T3
<
Kg
ITf E  O
"l ^2
4-azoben-
zenesul-
phonic
acid
3.65 0.929 1.14 4.61 4.79 2.37 1.73 6.48
Mordant 
Yellow 10 7.82 3.90 2.93 2.68 6.76 2.08 3.25 3.29 ■
4-hydroxy- 
azobenzene 
4'sulphonic 
acid
2.33 1.65 2.17 4.18 2.96 7.58 2.37 4.43
Mordant 
Yellow 7 2.00 1.06 3.41 6t87 1.91 1.49 3.28 4.52
5-phenyl­
azosali­
cylic
acid
3.81 4.08 1.31 9.39 4.57 3.24 1.75 11.66
Mordant 
Orange 1 2.52 1.15 2.28 14.62 1.14 2.31 3.08 16.67
Alizarin 
Yellow GG 3.71 2.18 5.46 10.90 5.98 0.766 4.18 14.89
Mordant 
Yellow 12 1.60 1.53 4.31 17.70 3.78 1.04 4.47 13.39
Table 8.1. Table of binding parameters for the series of 
azobenzene derivatives
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-4.0
n
-3.0
•H
• 1.0
2.0 3.0
Total dye concentration/lo”"^ mol dm
1.0 4.0
-3
Fig. 8.1. Theoretical binding extent plots for azo dyes 
with human serum albumin (1.000 x 10-5 
mol dm-3) (U.V./visible data fitting method)
1. 4-azobenzene sulphonic acid
2. Mordant Yellow 10
3. 4-hydroxyazoben ze-4'-sulphonic
4.
acid
Mordant Yellow 7.
5. 5-phenylazosalicylic
acid
6 . k^)rdant Orange 1
7. Alizarin Yellow GG
8 . î^ordant Yellow 12.
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m
2.0 3.0 4.0
Tbtal dye concentration/lo” mol dm
Fig. 8.2. theoretical binding extent plots for azo dyes __ 
with human serum albumin (1,000 x ICr^ mol dm ) 
(Ultrafiltration method)
1. 4-hydroxyazobenzene-4'-sulphonic acid
2. Mordant Yellow 10
3. 4-azobenzene sulphonic acid
4. Mordant Yellow 7
5. 5-phenylazosalicylic acid
6 . Alizarin Yellow GG
7. Mordant Yellow 12
8 . Mordant Orange 1.
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8 .6 . Correlation between structure and binding 
characteristics
In order to establish any correlation between structural 
features of molecules and the degree to which they bind to 
H.S.A. it is useful to rank the various binding parameters 
for the compounds used. (Table 8.2)
In terms of the total binding of the compounds to
H.S.A. (fig. 8,1 and 8.2), the two methods correlate well.
The three weakest binders, 4-azobenezenesulphonic acid. 
Mordant Yellow 10 and 4-hydroxyazobenzensulphonic acid are 
all acids containing a sulphonate group. As such they are 
likely to be less hydrophobic than members of the group con­
taining only a carboxylate group as the base function. In 
both series of experiments Mordant Yellow 7 is next in terms 
of total binding. The introduction of the methyl group to 
the salicylate ring is likely to increase hydrophobicity 
although the strength of binding may be offset to some extent 
by steric hindrance. The trend of increasing binding with 
increasing hydrophobicity continues with 5-phenylazosalicylic 
acid. Introduction of a nitro or amino-group to the phenyl 
ring increases the extent of binding further, and must be 
attributable to a specific interaction between these groups 
and a receptor site on the albumin molecule. It is not cer­
tain whether the individual values K2 h^ and n 2 have any 
physical significance. The degree to which the azo compounds 
are bound seems to be dictated largely by the value of n 2 , 
and there is good correlation between the ranking orders of 
total binding and the value of n2 for each series of experi­
ments. (Table 8.2) There is also good agreement between 
the ranking orders of n 2 for the two series of experiments.
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The ranked sequences of n^ ^ for the two series of experi­
ments, agree even more closely, although it is hard to 
correlate the sequence with structural features of the 
molecules. There is poor agreement between the two series 
of experiments for and K2 values and it must be concluded 
that although these values have similar orders of magnitude 
they are probably only of mathematical significance.
226
Tbtal
Binding ‘'i %2 "l ^2
Spectrophoto- 
metric method
4-ABSA MY12 4-ABSA 4-ABSA MYIO
increasing
va 1 IIP <5
MYIO MY7 MY7 5-PASA 4-OHABSA
4-OHABSA 4-OHABSA MOl 4-OHABSA 4-ABSA
MY7 MOl MY12 MOl MY7
5-PASA 4-ABSA 4-OHABSA MYIO 5-PASA
• MOl AYGG AYGG MY7 AYGG
AYGG 5-PASA MYIO MY12 MOl
\ MY12 MYIO 5-PASA AYGG MY12
Ultrafiltra­
tion method
4-OHABSA MOl AYGG 4-ABSA MYIO
increasing
values
MYIO MY7 MY12 5-PASA 4-OHABSA
4-ABSA 4-OHABSA MY7 4-OHABSA MY7
MY7 MY12 MYIO MOl 4-ABSA
5-PASA 5-PASA MOl MYIO 5-PASA
AYGG 4-ABSA 4-ABSA MY7 MY12
MY12 AYGG 5-PASA AYGG AYGG
V MOl MYIO 4-OHABSA MY12 MOl
Table 8.2. Ranked binding data for the two series of
experiments
Abbreviations :- 4-ABSA = 4 azobenzenesulphonic acid
4-OHABSA = 4-hydroxyazobenzenesulphonic acid
5-PASA = 5-phenylazosalicylic acid
AYGG = Alizarin Yellow GG
MYIO = Mordant Yellow 10
MY7 = Mordant Yellow 7
MOl = Mordant Orange 1
Myl2 = Mordant Yellow 12
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8.7. Comparison of Spectrophotometric and Ultrafiltration 
methods for studying dye-protein interactions
8.7.1. Spectrophotometry
The most striking advantage of this technique is the 
reproducibility which can be obtained. For any particular 
dye-albumin mixture, titrations of dye with albumin give 
values of absorbance which agree to within 1%. The tech­
nique has the advantage of having only one phase, thereby 
eliminating the problems of dye membrane association en­
countered with multiphase methods such as dialysis and 
ultrafiltration. The method requires only small quantities 
of reagents, and, since determination is rapid, problems 
of reagent deterioration are removed.
The method is applicable to ligands with appreciable 
absorbances at wavelengths longer than 300nm. (At shorter 
wavelengths albumin absorbs radiation strongly, changes 
in the protein spectra are more complex than those of the 
dye, possibly as a result of configurational changes).
Assuming that the two independent site model is a 
reasonable approximation to the real system, the technique 
has the advantage that changes in the concentration of all 
three dye components are being observed at the same time. 
With dialysis or ultrafiltration the concentration of only 
one component is measured. Under certain conditions the 
ratio of the two bound species (which depends on the rela­
tive binding constants of the two species) can vary by 
large amounts whilst the free dye concentration remains 
fairly constant. It is essential that the spectrophoto­
meter used for the determinations has good precision and 
reproducibility in both absorbance and wavelength readings.
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(The Perkin Elmer 555 used in this study specifies a 
precision of - 0 ,2nm in the wavelength reading and -
0.002A at 1A in the ordinate reading).
There is also a certain amount of qualitative infor­
mation which can be drawn from the spectral changes both 
in terms of amplitude and direction of shift in wavelength 
of the spectra.
The technique does suffer from the drawback that only 
a limited range of dye-albumin concentrations can be 
studied. It also has the necessary prerequisite that the 
ligand studied must show changes in their U.V/visible 
spectra when added to albumin or some other protein in 
question.
8.7.2. Ultrafiltration
The main advantage of the technique is that free dye 
concentrations are measured directly, and not via an inter­
mediate theoretical step.
The technique is fairly rapid and compares favourably 
in this respect with the spectrophotometric method. Theo­
retically the method is simple, provided that no account 
has to be made of dye rejection. The technique is appli­
cable to any dye-protein system provided that there are no 
serious membrane binding or rejection problems. Any dye- 
protein ratio can be studied provided that the effluent 
dye concentration is large enough to be measured. This is 
a considerable advantage over the spectrophotometric method 
in which the concentrations which can be used are rather 
limited.
As well as the problems of rejection and membrane
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binding, the technique requires rather large quantities 
of reagents. It does not provide any qualitative infor­
mation. Experimental data points exhibit a rather large 
degree of scatter {- 3.5% at high dye concentrations and 
as high as - 18% at low dye concentrations).
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8.8. The spectrum of azobenzene
Isoelectronic molecules in many instances have similar 
electronic spectra. Azobenzene and stilbene are isoelec- 
tronic and they, as well as other azobenzene derivatives, 
exhibit very similar electronic spectra. They consist of 
a very intense band at relatively long wavelength, varying 
from about 300nm in stilbene to about 420nm in the conjugate 
acid of azobenezene. A second band occurs with lower in­
tensity at about 230nm in all compounds. In addition, 
some of the compounds have an additional low-intensity
TOO
band at longer wavelength. Jaffe and Orchin assign the 
high intensity long wavelength band to the - ^A transi­
tion, since this transition should occur at the longest 
wavelength and its great intensity identifies it as a V - N 
transition. The shorter wavelength transition is insensi­
tive to the nature of the bridge bonding the phenyl groups, 
provided that the conjugation of the system is not signi­
ficantly altered. This indicates that either both upper 
and lower energy levels are equally displaced, or that 
neither is displaced at all by modification of the bridge.
Making reasonable assumptions for Coulomb and resonance
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integrals for the various bridge atoms it can be shown 
that the energy levels of the two occupied symmetric orbi­
tals (v orbitals) and the corresponding unoccupied ones 
(w orbitals) are unaffected by the bridging group. Accor­
dingly Jaffe and Orchin^^^ assign the short wavelength 
band to a - ^A transition. The spectral characteristics 
of some analogues of azobenzene are reproduced in Table
8.3.
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8.8,1. Solvent effects
The strongest U.V, band in azo compounds undergoes 
a shift towards the blue upon passing from a polar to a 
non-polar solvent. Thus azobenzene^^^ has a peak maximum 
at 342nm in ethanol, but at 338.5nm in hexane. Corres­
pondingly there is a small increase in the value of the 
extinction coefficient at the wavelength of maximum absor­
bance on passing from ethanol to hexane.
8.9. Spectral changes on binding of Azo-dyes to H.S.A.
When the series of azobenzene derivatives in this study 
bind to H.S.A., the long wavelength band corresponding to 
the V - N transition undergoes changes which have a number 
of features in common which may be summarised as follows:- 
All the spectra exhibit a shift to longer wavelength 
on addition of H.S.A.
From the calculated spectra which used the two 
independent site model, two further observations can be 
made.
(a) In almost all cases the spectrum of the more strongly
bound species moves towards the red by about 10-30nm.
The value of the extinction coefficient at Xmax for 
the more strongly bound species- being roughly the 
same as for the free species.
(b) In most cases the spectrum of the more weakly bound
species moves towards the red by only a small amount
(less than lOnm). The value of the extinction co­
efficient at Xmax being smaller than that of either 
the free dye or the strongly bound species.
Even if the two independent site model is incorrect 
any equilibrium model used to explain the spectral changes
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will show that the more weakly bound dye species shows a 
decrease in the extinction coefficient at Xmax and a small 
red shift, whilst the more strongly bound species have 
larger extinction coefficients at Xmax and show a larger 
red shift. '
The question that immediately arises is whether, as 
Klotz suggested (Ch.l p 4 1), 'optical displacement is a 
measure of degree of binding'. The red shift in the spectra 
upon saturation of the dyes with H.S.A. are summarised in 
Table 8.4.
Compound Red shift/nm
4-ABSA 6
4-OHABSA 6
5-PASA 8
MY7 9
MYIO 11
AYGG 12
MY12 14
MOl 22
Table 8.4. Summary of red shifts in the azo- 
dye spectra.
Although these red shifts are only approximate, it is 
apparent that the .three strongly binding dyes also show 
relatively large red shifts. In terms of the resolved
spectra from the two site model, there is hardly any cor­
relation between the degree of binding and red shifts of the
spectra as shown in Table 8.5.
Compound Red shift in 
/nm
Red shift in 
/nm
4-ABSA 1 0 5
4-OHABSA 1 0 5
5-PSSA 15 <5
MY7 20 <5
MYIO 15 <5
AYGG 15 <5
MY12 15 5
MOl 30 15
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Table 8.5
It would appear, therefore, that the largest displacements 
do occur in the strongly bound dyes, it is not possible 
to predict the order of binding strength solely by 
measuring the red shift in the observed spectra.
8.10. The nature of dye-H.S.A. interactions
It has been suggested by some workers^^^ that H.S.A. 
preferentially binds anionic drugs by some form of electro­
static interaction. From the work described here it seems 
most unlikely that ionic interactions are the chief 
mechanism by which azo dyes are bound to H.S.A. If this 
were the case then the diacids such as Mordant Yellow 
10 and Mordant Yellow 7 (for which both carbonyl and 
sulphonate groups are totally dissociated at pH 7.4).would 
be expected to be the most strongly bound dye, whereas, 
in fact. Mordant Yellow 10 is one of the most weakly 
bound dyes. Furthermore,• in terms of electrostatic attrac­
tion, both of these dyes should bind equally, if there 
were any difference in binding. Mordant Yellow 7 would be 
expected to be the weaker due to steric hindrance by the 
methyl group in the salicylate ring. In fact. Mordant 
Yellow 7 is more strongly bound than Mordant Yellow 10.
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Hydrophobicity appears to be an important factor in 
the degree to which dyes are bound by H.S.A. It might be 
suggested that since all the dyes used are hydrophobic, 
binding of the dyes to the protein might be comparable 
to the solvent distribution that would occur if an organic 
solvent were introduced to an aqueous solution of the dye, 
i.e. the dye will distribute between the organic environ­
ment of the protein and the aqueous solution in much the 
same way as it would distribute between aqueous and organic 
phases.
Hydrophobic effects have been suggested by many 
workers to be the major contributing factor in the inter­
action of proteins with most neutral drugs. The term
"hydrophobic bonding" may, in fact, be a misleading 
13 7 138term. * It seems likely that bonding of this type is
entropically driven, largely as a result of the disruption
of the quazi-crystalline water structure around the non-
139polar groups in aqueous solution.
Hansch et al^^^ have found excellent correlation 
between binding of various compounds to bovine serum al­
bumin and the partition coefficients of the compounds 
between octanol and water.
Scholtan^^^ has shown that for some sulphonamides, 
antibiotics, cardenolides and steroid hormones, series of 
these compounds show increased binding with the increasing 
hydrophobic character of their members. Similarly series 
of penicillins^^Z, p-hydroxybenzoic acid esters^^^, and 
homologous series of fatty acids^^^, sulphates, sulphonates
and alcohols^^S, 146^ hydrocarbons^^? aromatic compounds
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14 8
and alkanes , have all been shown to bind more strongly 
as the hydrophobicity of their members is increased.
However, binding of the azo-dyes is not entirely 
analagous with partitioning of the dyes between water and 
an organic solvent. On binding, the dye spectra undergo 
a red shift, rather than the expected blue shift asso­
ciated with a change to a less polar environment. There 
is also a decrease, rather than an increase, in the value 
of their extinction coefficient at Xmax. Furthermore, 
spectral shifts associated with solvent changes are small 
(rarely more than 5nm), which suggests that binding between 
the dye molecules and H.S.A. involves forces other than 
those of the solvent-partitioning type of effect. The 
spectral changes of the azobenzene analogues in Table 8.3 
may yield a clue to the binding forces involved.
Azobenzenes conjugate acid shows a strong red shift 
of 104nm for its <- ^A U.V. band, and a corresponding 
increase in the extinction coefficient at Xmax. Azoxy- 
benzene and its conjugate acid also exhibit red shifts in 
comparison with azobenzene although in these cases there 
is a decrease in their extinction coefficients at xmax.
It would appear, therefore, that the spectral changes in 
this work are consistent with the dye azo-group donating 
electrons to an electrophilic group on the albumin molecule, 
and that any potential binding site should contain an elec­
trophilic group.
Residues such as tyrosine, phenylalanine and trypto­
phan may all potentially form complexes by delocalisation 
of electrons into their «-systems.
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It seems likely, therefore, in view of the apparent 
correlation between binding and hydrophobicity, and the 
probability of electron donation by the azo group, that the 
strongest binding sites will be those in highly apolar regions, 
with an electron accepting group. One such possibility is 
in the tryptophan region of the H.S.A. molecule.
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Lys. Ala. Trp. Ala. Val. Ala Arg.
This region has been suggested by Reynolds et alî’^ ^ as a 
likely binding site for organic molecules.
Introduction of an a amino group to the phenyl ring 
in Mordant Yellow 12 increases the extent of binding. This 
must be due to binding with further acidic sites on the al­
bumin molecule. Mordant Orange 1 and Alizarin Yellow GG, on 
the other hand, containing nitro groups in their phenyl ring 
are likely to bind to basic regions containing groups such 
as arginine or lysine.
The question of the location of drug binding sites on
H.S.A. has been discussed by a number of authors. Fehske 
14 9et al. have reviewed much of the work and concluded that
H.S.A. has at least five identifiable binding sites.
I. Indole and benzodiazepine binding site
The site binds several indole derivatives and benzo­
diazepines, as well as L-tryptophan, diazepan, dansylsar- 
cosine, iopanoic acid, and fluorbiprofen , it also binds many 
other drugs with very different structures. The site is 
thought to be formed, as a result of the tertiary structure 
of H.S.A., between several regions on the molecule. The 
major part of this binding site lies between residues 124- 
298, but parts of this site may be also located in the frag-
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ment containing residues 299-585. Arginine 145, Histidine 
146, and Lysine 194 are involved in this site, as also is 
Tyrosine 410.
2. Warfarin and Azapropazone binding site
It is thought^^^' 152, ^hat this site is composed
largely of Tryptophan 214, since modification of this resi­
due reduces the binding of Warfarin and iodipamide to this 
site. However, modification of the residue does not affect 
the binding of Azapropazone, and it was concluded that, in 
fact, the region consists of two overlapping sites. It 
seems very likely that the Warfarin site binds the azo dyes 
studied here since this site is known to bind salicylic acid
derivatives as well as W a r f a r i n , a n d  a very large number
123of unrelated drugs.
3. Dig .itoxin binding site
The site is specific for few drugs. The position and 
nature of the site is as yet unknown, although some tyro­
sine residues have been implicated.
4. Bilirubin binding site
Bilirubin binds to at least two binding sites, evi­
dence as to the exact nature and position of the site is 
contradictory, although it is known that bilirubin inhibits 
the binding of typical Warfarin site binders.
5. Fatty acid binding site
Again, the exact position of the site has not been 
identified, although the region around amino acid residue 
422 has been suggestedl^^' The site is not thought to
be identical with the Warfarin site, but may be one of the 
bilirubin sites.
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Fig.8.3. Theoretical binding extent plot for Bromophenol 
Blue with human serum albumin (1.000 x 10~^ 
mol dm~^) (U.V/visible data fitting method).
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8.11 Competition reactions
Competitive interactions between organic molecules 
and serum albumin have been well known for many years t 
Klotz conducted some competition experiments between azo- 
sulphathiazole and various simple organic acids, and was 
able to rank them in order of strength of competition.
It has already been pointed out that binding sites 
may be classified according to the displacement of certain 
marker compounds from them.
Although semi-quantitative competition experiments 
are well known, the quantitative treatment of competitive 
systems has not been dealt with in such detail.
Meisner et al. have described a-study of the inter­
action of bovine serum albumin with the ligand-competitor 
pairs, (1) octanoate-chlorophenoxyisobutyrate (2) palmitate- 
stearate (3) stearate-chlorophenoxyisobutyrate and (4) 
8-anilinonaphthalenesulphonate (A.N.S.)-chlorophenoxyiso- 
butyrate. Using a simple two independent neutral site 
model such as will be described below, they were able to 
account for the competitive interactions of the pair (1) 
and (2), but not (3) and (4).
Kalbitzer and Stehlik^^^ have described in some detail 
various mathematical models for competitive macromolecular 
interactions. They consider the case of a single binding 
class of independent sites. They also consider the case 
of competing ligands for cooperative as well as independent 
binding sites.
Although the mathematics for such systems can be 
developed relatively easily, except in the simplest case
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of one independent site, there is usually no intrinsic 
solution for the binding parameters. These must, therefore, 
be obtained by some form of fitting procedure.
It has already been shown that even for single ligands 
it is usually difficult to differentiate between models, 
and the problem must become more acute when even more un­
known binding parameters are introduced into the equations 
to be fitted.
8.11.1. Bromophenol Blue as a competitor
Bromophenol Blue was chosen as a competitor because 
it was found to undergo competition reactions with all the 
azobenzene derivatives studied. In.addition, it has a 
spectrum with absorption bands at significantly higher 
wavelengths than the azo dyes. Therefore, the spectral 
changes monitored at these wavelengths are independent of 
the spectral changes in the competing azo dye. Further­
more these spectral changes of Bromophenol Blue, on addi­
tion of H.S.A., are large in comparison with those obser­
ved for many dyes.
Bromophenol Blue is seen to be a relatively weakly 
bound dye if Fig.8.3 is compared with Fig.8.1 and 8.2.
As such it should be easily displaced from H.S.A. by the
competing dyes.
In retrospect it might have been better to have 
chosen another azo dye, e.g. Evans Blue, as the standard 
displaced ligand, since this may have reduced the possi­
bility of there being non—mutual binding sites on the
albumin molecule.
242
8.11.2. Sequence of strength of competition
From Fig.7.4 and 7.5 the strength of competition at
albumin concentrations of between 1.5 and 3.0 x 10“  ^ mol 
— 3
dm” for the dyes is in the order
MY12 4-OHABSA MOl 4-ABSA MYIO MY7 AYGG 5-PASA 
(for abbreviations see above p226)
If the Mordant Yellow 12 and Mordant Orange 1 and 
Alizarin Yellow GG curves are disregarded, then the se­
quence is exactly that of the ultrafiltration experiments, 
except that the positions of Mordant Yellow 10 and 
4-azobenzenesulphonic acid are reversed.
8.11.3. Improvements to the Model
The double independent mutual site model seems to be 
a very poor method for obtaining competitor dye binding 
constants. In no case are the values of and ob­
tained from the competition experiments, consistent for a 
range of dye concentrations.
Probably the simplest improvement would be to consi­
der that there are four classes of site present in the 
system. The first class is the Bromophenol Blue primary 
site (S„T ) to which the competitor dye may also bind with 
an equilibrium constant of The second class is a
primary site (S^^) to which the dye also binds, with the 
same affinity as to but from which Bromophenol Blue
is excluded. Similarly there are corresponding secondary 
sites. Thus the following equilibria can be written:—
BSgi = [BSsi] (G.l)
[BfjCSei]
K, 243
D + Sfli ^ DSg^ = [DSg^] (8.2)
K
° + ^D1 - DSni = [PSpi] (8.3)
T s^TTTd T
®f ■'■ ®B2 " BSg2 Kg2 = [BSg2] (8.4)
K2
T s^ P T b^]
D + Sg2 - DSg2 K2 = [DSg2] (8.5)
r s ^ ]
K
D + Sd2 - DSg2 K2 = [DSg2] (8.6)
The following relationships may also be written
[Dtot] “ + [OSsi] + [DSB2] + [DSni] + [DScZ^ (8.7)
= [Bf] + [BSg^] + [BS3 2 ] (8 .8 )
[^Dltot] “ + [Sol] (8.9)
^^D2tot^ “ (8.10)
[Ssitot] = [^Bl] + [BSgi] + [DSg^] (8.11)
[SB2tot] = [Ss2] + [8832] + [DS32] (8.12)
where :-
[BSgi] = the concentration of Bromophenol Blue bound 
at the common primary site.
[B^] = the concentration of free Bromophenol Blue
[Sg^] = the concentration of unbound common primary
site
[DSb i ] = the concentration of competitor bound at the 
common primary site 
[D] = the concentration of free competitor
[BSb2 ] = the concentration of Bromophenol Blue bound
at the common secondary site 
[Sgg] = the concentration of unbound common secondary 
site
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“ the concentration of competitor bound at the 
common secondary site 
[^0 %] ~ the concentration of unbound, Bromophenol Blue
excluded, primary site 
~ the concentration of unbound, Bromophenol Blue 
excluded, secondary site 
^ the total competitor concentration 
= the total Bromophenol Blue concentration 
[Sg2 ^Q^]=the total Bromophenol Blue excluded, primary 
site concentration
total, Bromophenol Blue excluded, secondary 
site concentration
[ S
B2tot]=the total common secondary site concentration
^Bl' ^B2'l31^^^ ^D2 numbers relating the cor­
respondingly subscripted total dye concentration to the 
total protein concentration ([P]) then:-
[^Dltot^ = ^DiCP]
[^D2tot]
^^Bltot^ = ng^[P]
^^B2tot^ = "b 2 [B]
If all K and n values were known then equations 8.1 to 
8.12 should be soluble since there are twelve unknown and 
twelve equations. Undoubtedly the most satisfactory way 
of fitting this model to experimental data would be to 
guess K and n values, calculate [BS^^], [BSgg] and [B] 
and from the known extinction coefficients of these three 
species to calculate theoretical absorbances of a series 
of solutions. The K and n values could be refined to 
minimise the difference between measured and theoretical 
absorbances in much the same way as described in Chap. 4.
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The equations can easily be reduced to two equations 
in two unknowns, but, unfortunately, both involve a cubic 
term. This means that on substitution there are nine pos­
sible solutions. Although, on re—substitution some values 
give unrealistic values for the other unknown concentra­
tions, there are still a number of possible real solutions.
It has not been possible to write a curve fitting routine 
which can effectively resolve this situation.
A further possibility would be to re-arrange equations 
(8.1), (8.2) and (8.3)
(8.13)
[DSg^] = Kj^[Sgj^][D] (8.14)
[DSg^] = Kj^[Sgj^][D] (8.15)
Substituting these equations into (8.9) and (8.11)
[SoitOt: = Kl[Sgi][D] + [S^] (8.16)
Sgltot = [BSsl] + [BSgi] + K^[BSg^][D] (8.17)
and thus by substitution and re-arrangement
[Soi] = ^^Bl*-^Dltot^ (8.18)
• S l ® f )
A fitting routine could calculate values for BS^^, BSg2 
and B^ as previously, and, by guessing the K and n values, 
calculate [S^^]. By re-substitution into any equation 
other than (8.7) all other unknown concentrations can be 
calculated, since there are now only four unknowns and six 
unused equations (excluding equation 8.7).
The ‘goodness of fit' of the binding parameters is
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then assessed using equation 8.7 to calculate values
for the series of solutions, and comparing them with the 
actual values by the function:
^ = : 'C -
A better model might consider the existence of six classes 
of site, which as well as the four classes mentioned above, 
would include primary and secondary classes of site to which 
Bromophenol Blue could bind, but from which the competitor 
was excluded.
If the simple model by which the results in Chap. 7 
were calculated (Model 1) is compared with the first of 
the two models (Model 2) above, the results obtained can 
be largely explained. In Model 2 there are two effects 
which contribute to the degree to which competition occurs. 
The first of these is direct competition for the mutual 
binding sites between Bromophenol Blue and the competitor.
The second is the binding of competitor to the non-mutual 
sites. If the competitor has a large number of non-mutual 
sites available, then much of the dye will be bound at 
these sites and the free dye concentration much reduced.
The dye will thus effectively become a weak competitor, 
even though it has a larger affinity for the mutual sites 
than another competitor which has fewer non-mutual sites.
Since Model 1 ignores the existence of non-mutual sites 
the free dye concentration will be lower than it should be 
since the equilibrium constants are calculated from the 
equation :-
K. = [DS^]
[D][sTT
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will be larger than it should be. Furthermore the 
effect will be worst at low competitor concentrations, 
and so will decrease as the total concentration of 
competitor increases. This is seen in Tables 7.8 and 7.9 
to be generally the case.
The largest errors in the values of will also 
occur at low dye concentrations. The competitive effect, 
and thus the differences between the Bromophenol Blue 
spectrum in the presence and absence of competitor, will 
be smallest at these concentrations.
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8.12. Conclusions
In conclusion this study has shown that spectro­
photometric changes in the spectra of organic acids are 
compatible with binding to human serum albumin. Changes 
in binding characteristics brought about by changes in 
structure of the series of azobenzene derivatives agree 
with previous theories for the binding of organic acids 
to serum albumins, hydrophobicity being the most important 
factor. It seems likely that the lone tryptophan residue 
of the Warfarin binding site is at least partly involved 
in the binding of these compounds.
Although the ultrafiltration technique gives less re­
producible results than the spectrophotometric method it 
gives a direct measure of binding of a ligand to a protein.
It seems that the ligand binding curve is more meaningful 
than individual binding parameters. It is essential to 
realise that in most data fitting routines there are always 
a number of equally, mathematically correct, parameter sets. 
It is also important to measure spectral changes over as 
wide a range of concentration and wavelength as possible, 
single wavelength measurements are subject to large errors 
in fitting techniques. This should be borne in mind when 
comparing rate constants obtained from single wavelength 
measurements with the equilibrium constants.
Bromophenol Blue is displaced from human serum albumin 
by the azobenzene derivatives, and the spectra of Bromo— 
phenol Blue -albumin mixtures in the presence of these dyes 
are in agreement with this observation. Even so the spec­
tral changes have only been partially interpreted and a
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full description of these competitive reactions awaits 
explanation.
Further studies with a larger series of azo dyes 
should enable one to obtain quantitative structure activity 
relationships for binding of such dyes to albumin. A 
study of pH effect and comparisons of binding with other 
albumins, e.g. bovine, horse etc., may enable the sites 
of binding to be given with more certainty. Use of Warfarin 
as a competitor was not considered because of its position 
of absorption and because the reproducibility of data 
using Warfarin is rather poor. Almost each group of 
workers produces a new set of binding parameters.
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APPENDIX 1
PROGRAM FOR MATRIX RANK ANALYSIS
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